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Alzheimer’s disease (AD), a neurodegenerative disease characterized by progressive 
cognitive decline, is becoming increasingly prevalent as the population ages. There 
is no effective treatment for AD, so manipulating modifiable risk factors before 
clinical symptoms of dementia develop may be the most effective course to prevent, 
delay, or modify the course of AD. Type II diabetes mellitus (DM), characterized by 
hyperglycemia and insulin resistance, affects over a quarter of older adults and has 
been linked with AD, cognitive decline, and brain atrophy. Because DM is 
preventable and treatable, it represents an intervention target for AD. This 
dissertation investigated the association between glucose levels and three outcomes 
– performance on a battery of cognitive tests over time, time to symptom onset of 
mild cognitive impairment (MCI) or dementia, and cortical thickness in AD-
signature regions (i.e., entorhinal cortex, inferior temporal gyrus, parahippocampal 
gyrus pars triangularis, precuneus, superior frontal and parietal gyri, supramarginal 
gyrus, and temporal pole). Additionally, it investigated how two genes – 
apolipoprotein E (APOE) and translocase of the outer mitochondrial membrane 
(TOMM) 40 – may modify the relationship between glucose and these outcomes. 
Both the APOE ε4 allele and the TOMM40 very long/very long (VL/VL) genotype 
(versus the short/short (S/S) genotype) have been associated with increased risk of 
dementia, cognitive decline, and brain atrophy, and some evidence suggests that 
these genetic factors may further increase the risk in individuals with DM. This 
research was conducted using data from the BIOCARD Study (n=349), which 
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enrolled primarily middle-aged individuals, three-quarters of whom had a first-
degree relative with dementia. The goal of the study was to examine the early signs 
and symptoms of AD in a high-risk cohort. For this dissertation, baseline blood 
glucose level, which was ascertained from a blood draw in a clinical exam, was the 
primary predictor and was available for 333 participants. APOE and TOMM40 
genotypes were also determined from blood samples. Age of MCI or dementia 
symptom onset was determined through consensus diagnosis. At annual visits, 
participants completed a neuropsychological test battery, and at baseline and bi-
annually, participants completed magnetic resonance imaging (MRI) scans. The first 
paper in this study used linear mixed effects models (LMMs) and generalized 
estimating equation (GEE) models to investigate the association between glucose 
and cognitive performance over time. We used confirmatory factor analysis (CFA) to 
create one factor based on performance on tests of executive function (the executive 
function factor) and one factor based on performance on tests of memory (the 
memory factor). We found that higher baseline glucose was associated with greater 
decline on the executive function factor score in both LMMs (B=-0.005; 95% CI -
0.008, -0.001) and GEE models (B=-0.004; 95% CI -0.007, -0.001) that controlled for 
age, sex, race, education, depression, and medical conditions (i.e., cardiovascular 
conditions, hypertension, hypercholesterolemia, traumatic brain injury (TBI)). 
Interaction analyses using LMMs found that higher glucose was associated with 
significant decline in executive function score in ε4 carriers (B=-0.013; 95% CI -
0.020, -0.006), but not in non-carriers (B=-0.002, 95% CI -0.006, 0.002). In LMMs, 
higher glucose was also associated with poorer memory factor score over time in 
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subjects with the S/S genotype (B=-0.013; 95% CI -0.024, -0.002), versus the VL/VL 
genotype (B=0.004; 95% CI -0.003, 0.010). The second paper in this study used Cox 
proportional hazard models to investigate the association between baseline blood 
glucose level and time to MCI or dementia symptom onset, as well as the association 
between the interaction of APOE and glucose and TOMM40 and glucose and time to 
symptom onset. We did not find an association between glucose level and time to 
symptom onset; additionally, we did not find that APOE or TOMM40 modified this 
relationship. In the final paper, linear regression analyses showed that glucose level 
was associated with reduced cortical thickness in the parahippocampal gyrus (B=-
0.002; 95% CI -0.003, -0.0001) and temporal pole (B=-0.002; 95% CI -0.003, -
0.0002) in a fully-adjusted model. Additionally, higher glucose levels were 
associated with thinner measures of the superior parietal gyri (B=-0.001; 95% CI -
0.002, 0.0005 vs. B=0.0007; 95% CI 3.05e-6, 0.001) and temporal pole (B=-0.004; 
95% CI -0.008, -0.0009 vs. B=-0.0003; 95% CI -0.002, 0.001) in ε4 allele carriers 
versus non-carriers. This evidence suggests that even in middle-aged, cognitively 
healthy samples, higher levels of glucose, even in those without DM, can negatively 
impact cognitive performance and cortical thickness. Maintaining normal blood 
glucose levels may be important in middle age for reducing risk of cognitive decline, 
AD, and brain atrophy.  
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PROBLEM STATEMENT  
 The population is aging; adults over the age of 65 are the fastest growing 
segment of the population (Administration on Aging, 2013). Although the older 
adult population suffers from several chronic conditions and diseases, two of the 
most burdensome and prevalent – Alzheimer’s disease (AD) and type II diabetes 
mellitus (DM) – appear to be connected. Currently, there is no cure for AD, so 
identifying AD earlier in the disease course and intervening on modifiable risk 
factors may be the most effective path to mediate the burden of the disease.  
Alzheimer’s Disease  
Over five million older adults in the United States have dementia, and AD is 
the leading cause of dementia, accounting for approximately 60 to 80 percent of 
cases (Alzheimer's Association, 2014; Hebert, Weuve, Scherr, & Evans, 2013). By 
2050, the number of people over the age of 65 with AD is expected to triple to 13.8 
million (Hebert et al., 2013). Worldwide, the number of people with AD is expected 
to double every 20 years, which means it will affect 81.1 million people by 2040 
(Ferri et al., 2005). AD is a chronic neurodegenerative disease that is both 
emotionally and economically burdensome. The hallmark of AD is progressive 
decline in memory and cognition (American Psychiatric Association, 2013). AD 
patients also have significant functional decline and often have behavioral 
symptoms (e.g., agitation, aggression, and inappropriate affect), and as the disease 
progresses patients also have problems speaking, walking, and eating (Alzheimer's 
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Association, 2014). AD is the fifth leading cause of death in older adults; however, 
due to reporting error, it is likely that the number of people who die with or due to 
AD is underestimated (Alzheimer's Association, 2014; Murphy, Xu, & Kochanek, 
2013).  
Extracellular amyloid plaques, intracellular neurofibrillary tangles, and 
neuron death are the pathological characteristics of AD (Alzheimer's Association, 
2014). The brains of AD patients accumulate beta-amyloid protein fragments, which 
form the plaques, and tau protein, which are a major component of the tangles; as 
these proteins accumulate they lead to neurotoxicity and apoptosis (G. V. Johnson & 
Stoothoff, 2004; Sun, Bromley-Brits, & Song, 2012). The accumulation of beta-
amyloid and tau is thought to occur several years or decades before the symptoms 
of AD appear (Jack et al., 2013). While many individuals go undiagnosed until they 
develop clinical AD, some are diagnosed with mild cognitive impairment (MCI), 
which is often a prodromal stage of AD (Petersen, 2004). Like AD, MCI patients have 
cognitive decline, though it is not as substantial as in AD patients, and MCI patients 
do not have significant functional impairment (Petersen, 2004). Not all MCI patients 
progress to AD; however, approximately 10 to 20 percent of MCI patients convert to 
AD annually (Busse, Hensel, Guhne, Angermeyer, & Riedel-Heller, 2006; Fischer et 
al., 2007; Petersen et al., 1999).  
 Beyond the mortality rates associated with AD, it is a very difficult disease for 
patients, family and friends, and the health care system to manage (Alzheimer's 
Association, 2013). AD is also very costly to the health care system. It has been 
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estimated that in 2014 Medicare and Medicaid will pay 150 billion dollars for the 
care of AD patients, and total costs are expected to reach 214 billion dollars 
(Alzheimer's Association, 2014; Bynum, 2011). AD patients often need long-term 
care, skilled nursing care, medication, and hospital visits, all of which are costly. 
Further, AD patients often have other medical conditions (e.g., kidney disease, 
cardiovascular disease, diabetes), and compared to patients who have these 
conditions but do not have AD, those with AD have longer hospital stays and higher 
healthcare costs (Bynum, 2011). 
 As the prevalence of AD increases, the need to treat and/or prevent it is 
urgent. The strain that AD is placing on patients, families, and the healthcare system 
is unsustainable (Alzheimer's Association, 2013). Currently, there is no treatment 
for AD, so it is important to identify pathways for reducing the symptoms and 
decline, and possibly preventing onset of AD, earlier in the disease course.  
Type II Diabetes Mellitus  
  DM disproportionately affects older adults; over a quarter of the older adult 
population has DM and approximately half of the older adult population is thought 
to have pre-diabetes (American Diabetes Association, 2014b; Centers for Disease 
Control and Prevention, 2014). It should be noted that a recent article has suggested 
that the diagnostic criteria for pre-diabetes is too broad, and is leading to over-
diagnosis (Yudkin & Montori, 2014). However, it is also estimated that nearly 30 
percent of people with DM are undiagnosed (Centers for Disease Control and 
Prevention, 2014). Type II diabetes accounts for 90 percent of all diabetes cases 
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(World Health Organization, 2012). Type II diabetes begins with insulin resistance; 
this is a condition in which insulin, a hormone, cannot effectively enter cells and/or 
the pancreas is not able to produce enough insulin. Due to insulin resistance, 
glucose is not able to enter the cells to be used for energy, and therefore 
accumulates in the blood leading to high blood sugar (American Diabetes 
Association, 2014b). The diagnostic level for DM is a glycated hemoglobin (HbA1C) 
level of 6.5 percent or higher or fasting blood glucose of 126 mg/dL or higher. Pre-
diabetes, the prodromal stage of DM, is diagnosed at a HbA1c level between 5.7 and 
6.4 percent or a fasting blood glucose between 100 and 125 mg/dL (American 
Diabetes Association, 2014a). DM increases the risk of dementia, as well as 
hypertension, hypercholesterolemia, cardiovascular disease, stroke, neuropathy, 
and kidney disease, and it is the seventh leading cause of death across all age groups 
(American Diabetes Association, 2014b). In addition to the negative health 
outcomes associated with DM, it is also a very costly disease. The estimated total 
cost of DM, including both direct and indirect costs, was 245 billion dollars, in 2012, 
176 billion dollars of this were direct medical costs (American Diabetes Association, 
2014b). 
 Fortunately, type II diabetes is preventable and treatable. Many factors, 
including race, sex, age, diet, and activity level affect the risk of developing DM 
(American Diabetes Association, 2014b). However, DM can be prevented by 
avoiding insulin resistance and maintaining a healthy blood glucose level, generally 
through diet and moderate levels of physical activity (Knowler et al., 2002). Type II 
diabetes can be treated through diet and exercise, oral medication (e.g., metformin, 
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pioglitazone), or, if necessary, insulin injections (American Diabetes Association, 
2011). While it does not occur very often, DM can be treated so effectively that it is 
possible to revert to a prediabetic or normal state (Gregg et al., 2012).  
DM has been identified as a risk factor for AD. A recent study found that as 
many as one third of AD cases may be prevented by preventing risk factors for AD, 
including DM (Norton, Matthews, Barnes, Yaffe, & Brayne, 2014). Given that DM is 
so prevalent among older adults, and that it is so easily preventable and treatable, it 
may be that by targeting individuals who have or are at risk of developing DM, we 
may be able to delay the onset of AD or even prevent a significant number of AD 
cases from developing. As stated, DM is a risk factor of AD; it has been found that 
having DM increases the risk for AD by at least 50 percent (Cheng, Huang, Deng, & 
Wang, 2012). Further, DM has been found to negatively impact cognition and the 
rate of age-related cognitive decline (Lamport, Lawton, Mansfield, & Dye, 2009; 
Tuligenga et al., 2014). DM patients have also been found to have greater volumetric 
loss in several brain areas associated with cognitive function and that are affected in 
AD (Bryan et al., 2014; de Bresser et al., 2010; Falvey et al., 2013; Raber, Huang, & 
Wesson Ashford, 2004; Roberts, Knopman, Przybelski, et al., 2014; van Harten, de 
Leeuw, Weinstein, Scheltens, & Biessels, 2006).  
Two genetic factors have also been found to increase the risk of AD, and 
there is evidence suggesting that they may also be associated with DM. The 
apolipoprotein E (APOE) ε4 allele and the translocase of the outer mitochondrial 
membrane (TOMM40) long and very long alleles and genotypes (i.e., heterozygotes 
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or homozygotes) have both been linked to an increased risk of AD (Caselli et al., 
2012; Chartier-Harlin et al., 1994; Hayden et al., 2012; S. C. Johnson et al., 2011; Kim 
et al., 2011; Lutz, Crenshaw, Saunders, & Roses, 2010; Mastaglia et al., 2013; Roses 
et al., 2010; Shen et al., 2010). Additionally, studies have shown that individuals who 
have both DM and an ε4 allele have a greater risk of developing AD than those who 
have just one of those risk factors (Dore, Elias, Robbins, Elias, & Nagy, 2009; 
Vagelatos & Eslick, 2013). Similarly, physiological evidence suggests that a similar 
risk association may exist between DM, longer length of a poly-T nucleotide repeat 
of TOMM40, and AD (Hayden et al., 2012; Potkin et al., 2009).  
Apolipoprotein E 
 There are three allelic variations of the apolipoprotein E (APOE) gene – ε2, ε3, 
and ε4. The ε4 allele has long been associated with increased risk of AD (Chartier-
Harlin et al., 1994; Shen et al., 2010). Approximately 14 percent of the population 
are carriers of the ε4 allele, but 40 percent of AD patients are carriers (Farrer et al., 
1997). Both the heterozygous and homozygous genotypes have been associated 
with increased risk of AD, and the number of ε4 alleles is positively correlated with 
greater amounts of Aβ in the brain (Chartier-Harlin et al., 1994; Reiman et al., 2009; 
Shen et al., 2010). Evidence suggests that those with the ε4 allele have impaired 
clearance of Aβ from the brain (Bales, Dodart, DeMattos, Holtzman, & Paul, 2002).  
 The ε4 allele is associated with both risk of AD and earlier age of onset of 
sporadic AD (Corder et al., 1993; Farrer et al., 1997; Rebeck, Reiter, Strickland, & 
Hyman, 1993). Compared to individuals who are ε3 homozygotes, individuals who 
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are ε2/ε4 have a 2.6 times increased risk of developing AD; those who are ε3/ε4 
have a 3.2 times increased risk; and those who are ε4 homozygotes have a 14.9 
times increased risk (Farrer et al., 1997). However, it is important to note that these 
odds ratios vary by race and ethnic group, such that individuals who are ε4/ε4 have 
greater or smaller risk of developing AD based on their race/ethnicity. For example, 
African Americans with an e4 allele (odds ratio = 5.7) and Hispanics (odds ratio = 
2.2) are at substantially decreased risk compared to Whites (odds ratio = 12.5), 
whereas the Japanese (odds ratio = 33.1) have a substantially greater risk of AD 
(Farrer et al., 1997). The ε4 allele has also been found to be more prevalent amongst 
MCI patients (Pa et al., 2009), and MCI patients who have an ε4 allele have been 
shown to perform worse on memory tests and have faster cognitive decline across a 
number of domains compared to MCI patients without an ε4 allele (Cosentino et al., 
2008; Farlow et al., 2004; G. E. Smith et al., 1998; Whitehair et al., 2010). It has also 
been found that an ε4 allele is associated with greater memory deficits in cognitively 
normal persons (Caselli et al., 2007; Caselli et al., 2004).  
 These findings have also been supported by imaging studies; AD and MCI 
patients who are ε4 carriers have greater medial temporal lobe, and particularly 
hippocampal, atrophy compared to non-carriers (Hashimoto et al., 2001; Korf, 
Wahlund, Visser, & Scheltens, 2004; Petersen et al., 1995). Similarly, magnetic 
resonance imaging (MRI) studies have found that ε4 carriers have faster declines in 
cortical thickness and hippocampal volume, which are associated with poorer 
cognitive performance (Espeseth et al., 2008; Fennema-Notestine et al., 2011; 
Reiman et al., 1998). Functional MRI (fMRI) studies have found that even ε4 carriers 
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who do not exhibit Aβ aggregation have disrupted resting-state connectivity 
(Machulda et al., 2011; Sheline et al., 2010). Additionally, fMRI has shown that 
presence of an ε4 allele is associated with greater hippocampal activation during 
memory tasks, suggesting that ε4 carriers must use compensatory efforts in order to 
complete these tasks (Bondi, Houston, Eyler, & Brown, 2005; Bookheimer et al., 
2000; Filippini et al., 2009). Finally, presence of an ε4 allele may negatively impact 
synaptic plasticity; animal studies have found that ε4 is associated with fewer and 
shorter denditric spines (Dumanis et al., 2009; Klein, Mace, Moore, & Sullivan, 2010).  
 The role of APOE in the central nervous system is to take-up lipids, and 
reallocate them to cells for myelin generation or membrane repair; APOE is also 
involved in regulating glutamate receptor function and synaptic plasticity (Y. Chen, 
Durakoglugil, Xian, & Herz, 2010; Hauser, Narayanaswami, & Ryan, 2011). As 
previously mentioned, it is thought that individuals with an ε4 allele do not clear Aβ 
from the brain as efficiently as individuals without an ε4 allele. This may be because 
the protein Apoe-ε4 binds to Aβ with a lower affinity, as compared to Apoe-ε3 or 
Apoe-ε2 lipoproteins (LaDu et al., 1994). Aggregates of Aβ cause synaptic injury, 
apoptosis, and are thought to lead to dementia (Biennow, de Leon, & Zetterberg, 
2006; Hardy & Selkoe, 2002). It has also been found that ε4 carriers may be more 
susceptible to the types of neuronal stress that lead to tau phosphorylation, and 
therefore tangles (Aboud, Mrak, Boop, & Griffin, 2012; Liu, Kanekiyo, Xu, & Bu, 
2013). Further, ε4 animal models have shown that the ε4 allele is associated with a 
greater inflammatory response; this finding may explain why anti-inflammatory AD 
drugs are most effective in ε4 carriers (Lynch et al., 2003; C. A. Szekely et al., 2008).  
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Translocase of the Outer Mitochondrial Membrane (TOMM) 40 
 More recently, another gene, TOMM40, has been linked to AD risk. Within 
intron 6 of the TOMM40 homolog gene, the length of a poly-T nucleotide repeat 
(rs10524523, or “523” for short) has been found to be associated with risk of AD 
(Lutz et al., 2010; Roses et al., 2010). TOMM40 has three allelic variations – short (S), 
long (L), and very long (VL). Longer poly-T repeats (i.e., ≥ 27) are associated with 
risk of AD and earlier AD onset, while shorter poly-T repeats (i.e., ≤ 16 repeats) may 
be protective (Abraham et al., 2008; Grupe et al., 2007; Harold et al., 2009; G. Li et al., 
2013; Roses et al., 2010).  
Studies in the Alzheimer’s Disease Neuroimaging Initiative have shown that 
the very long/very long genotype is twice as prevalent in AD patients, and more 
common in MCI and is associated with hippocampal atrophy (Potkin et al., 2009; 
Shen et al., 2010). A case-control study found that, compared to those with the 
short/short genotype, individuals with one long allele had a 2.96 times increased 
risk of AD, and those with two long alleles had a 5.66 times increased risk of AD; 
additionally, those with long alleles had onset three years earlier as compared to 
those with the short/short genotype (G. Li et al., 2013). Further, the number of poly-
T alleles (i.e., one or two) was positively associated with the number of neuritic 
tangles present in the brain (i.e., Braak stages V-VI) (G. Li et al., 2013). Additional 
studies have found that longer TOMM40 poly-T length is also associated with poorer 
performance on episodic memory tasks (S. C. Johnson et al., 2011) and smaller 
hippocampal volume (Bis et al., 2012; Shen et al., 2010; Vounou et al., 2012). 
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However, some studies have not found an association between TOMM40 and AD 
(Cruchaga et al., 2011; Guerreiro & Hardy, 2012; Jun et al., 2012). It is also unknown 
whether TOMM40 is independently associated with risk of AD, or if it is tied to the 
risk associated with APOE genotype (Ferencz et al., 2013). It is difficult to separate 
the effect of the two genes because they are in linkage disequilibrium, meaning they 
recombine less frequently than if they were in random formation (Mastaglia et al., 
2013; Roses et al., 2010). 
 Although evidence is somewhat limited by small sample sizes, it appears that 
individuals with the APOE ε4/ ε4 genotype tend to have long poly-T repeats 
(between 21 and 30, with an average of 26.78 repetitions), while individuals with 
the APOE ε3/ ε3 genotype have a bimodal distribution of poly-T repeats, with peaks 
at 15.71 repetitions and 33.15 repetitions (Roses et al., 2010). To help determine 
the role of TOMM40 independently of APOE, some studies have examined only 
individuals with the APOE ε3/ ε3 genotype (S. C. Johnson et al., 2011; G. Li et al., 
2013). Despite this entanglement, some studies have found that TOMM40 is 
associated with APOE levels in the cerebrospinal fluid and expression of APOE in the 
hippocampus (Bekris, Galloway, Montine, Schellenberg, & Yu, 2010; Bekris et al., 
2008), suggesting TOMM40 plays a functional role in risk and development of AD (G. 
Li et al., 2013). Further, due to the relatively small body of research on TOMM40 and 
that most studies have been conducted in primarily Caucasian samples, the extent to 
which TOMM40 expression and length of the poly-T repeats vary by race or ethnic 
group is unknown (Roses et al., 2014). However, early evidence suggests, that like 
APOE, the risk association with AD and the length of poly-T repeats varies by race 
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and/or ethnic group. For example, in Caucasian populations the number of poly-T 
repeats spans from 14 to 39, but in African American populations the number of 
poly-T repeats spans from 14-54; it is not yet clear how these differences affect risk 
of LOAD and age of onset of LOAD (Roses et al., 2014). Future research conducted in 
more diverse samples is needed to elucidate any racial or ethnic group differences 
in TOMM40 expression. In conclusion, TOMM40 is important as it suggests that 
individuals who do not have an ε4 allele may also have increased genetic risk of 
developing AD.  
 The role of TOMM40 is to encode the mitochondrial pore protein, Tom40, 
which is, in part, involved in transporting Aβ into mitochondria (Hansson Petersen 
et al., 2008). Buildup of Aβ in the mitochondria may disrupt neuronal function 
(Caspersen et al., 2005). It has been suggested that the amyloid cascade begins with 
neurotoxic effects caused by both Tom40 and Apoe, or perhaps the interaction of 
the two, which releases cytochrome C (a protein involved in the electron transport 







BACKGROUND – Diabetes and Alzheimer’s Disease 
 DM is thought to increase the risk for AD and other dementias (Vagelatos & 
Eslick, 2013), be associated with age-related cognitive decline (Biessels, Strachan, 
Visseren, Kappelle, & Whitmer, 2014), and be associated with volumetric decline in 
several brain areas (van Elderen et al., 2010; van Harten et al., 2006).  
 Cross-sectional and longitudinal evidence has shown that DM and insulin 
resistance are associated with cognitive impairment and incident AD (Cukierman, 
Gerstein, & Williamson, 2005; Irie et al., 2008; Peila, Rodriguez, & Launer, 2002). As 
aforementioned, insulin resistance is caused by prolonged hyperinsulinemia, and is 
present in both diabetics and pre-diabetics. Having DM in mid-life has been 
associated with a three times increased risk of developing dementia, including AD, 
in later life (Schanider Beeri et al., 2004). In recent meta-analyses, it was estimated 
that DM is associated with a 1.33 to 2.05 times increased risk of AD (Lu, Lin, & Kuo, 
2009; Vagelatos & Eslick, 2013). Another meta-analysis examined 16 longitudinal 
studies that investigated the association between DM and AD; 10 of the studies 
found a significant association, while 6 did not; however, when all 16 studies were 
pooled together, there was a significant association between DM and risk of AD (G. 
Cheng et al., 2012). A study that used population attributable fraction calculations 
estimated that 6 to 10 percent of dementia cases are directly attributable to DM 
(Kloppenborg, van den Berg, Kappele, & Biessels, 2008). DM is also associated with 
risk of MCI. A meta-analysis that pooled two studies found that in the total of 2,484 
people, DM was significantly associated with increased risk of MCI (G. Cheng et al., 
2012). Additionally, DM may negatively affect MCI patients as well; it was found that 
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patients with both DM and MCI had faster cognitive decline than those with MCI, but 
without DM (Ravona-Springer et al., 2010). 
Diabetes and cognitive decline in specific domains 
 Several studies have also found that DM is associated with cognitive decline 
in those without dementia or MCI. Evidence suggests that developing DM in midlife 
and longer duration of DM is more greatly associated with decline in a range of 
cognitive domains. One study found that having DM in midlife was associated with 
diminished global cognition and executive function in late life (Roberts, Knopman, 
Przybelski, et al., 2014). Further, longer duration of DM, and the interaction between 
duration and poorly controlled DM, as measured by HbA1c levels, has been 
associated with poorer performance on attention and working memory, executive 
function, verbal fluency, and global cognition tasks (West et al., 2014). A recent 
study also examined rates of decline in DM patients (Tuligenga et al., 2014). The 
authors found that cognitively normal individuals (i.e., without a diagnosis of 
dementia or MCI) with DM had a 45 percent faster decline in memory, a 29 percent 
faster decline in reasoning, and a 24 percent faster decline in global cognition 
compared to cognitively normal persons without DM. These findings are substantial, 
as they translate to an equivalent 3.3 years of aging in memory, 2.9 years of aging in 
reasoning, and 4.4 years of aging in global cognition. These findings were further 
amplified in persons with poor glycemic control; those individuals showed even 
faster decline (Tuligenga et al., 2014).  
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 The association between glycemic control and neuropsychological test 
performance has also been widely examined. Hyperglycemia and hyperinsulinemia, 
below the threshold for a DM diagnosis, have also been found to be associated with 
poorer cognition. For instance, higher insulin levels are associated with worse 
global cognition, memory, executive functioning, attention, and verbal fluency; these 
findings were more substantial in persons without AD with higher insulin levels as 
compared to AD patients with higher insulin levels (Burns et al., 2012). Similarly, 
higher glucose levels were associated with poorer verbal and logical memory, 
delayed, immediate, and working memory, processing speed, and verbal and spatial 
ability in persons with neither DM nor dementia (Lamport et al., 2009; Seetharaman 
et al., 2014). Recently, a longitudinal study found that higher HbA1c levels in midlife 
are associated with cognitive decline over a 20-year period, and that more poorly 
controlled DM is associated with greater decline (Rawlings et al., 2014). These 
findings lend support to the theory that cognitive decline associated with DM begins 
in pre-diabetic stages, and then continues gradually (Biessels et al., 2014). It may be 
that cognitive decline caused by DM, hyperinsulinemia, and/or hyperglycemia 
lowers the threshold for the onset of dementia (Biessels et al., 2014). This may mean 
that DM truly starts to affect cognition in middle age, and later onset (i.e., past the 
age of 65) of DM may not affect risk of dementia or cognitive decline (Tuligenga et 
al., 2014). Therefore, treating or preventing DM in middle age is critical in order to 
reduce the risk or perhaps even prevent age-related cognitive decline and AD 
(American Diabetes Association, 2013; Vagelatos & Eslick, 2013).  
Diabetes and brain changes 
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The associations between DM and dementia and cognitive decline are further 
supported by imaging and autopsy studies. In DM patients’ brains there is 
substantial glucose dysregulation, inflammation, reduced perfusion, increased 
protein deposition, and increased oxidative stress, all of which negatively impact 
brain health (Kodl & Seaquist, 2008; L. Li & Holscher, 2007). Cross-sectional studies 
have consistently found that DM is associated with smaller brain volume (Bryan et 
al., 2014; Tiehuis et al., 2008; van Harten et al., 2006). Longitudinal evidence has 
shown that brain volume loss in DM patients is three times what is seen in persons 
without DM (de Bresser et al., 2010; Espeland et al., 2013; Kooistra et al., 2013; van 
Elderen et al., 2010). Specifically, middle-aged diabetics and pre-diabetics have 
greater atrophy in the hippocampus (Benedict et al., 2012; Convit, Wolf, Tarshish, & 
de Leon, 2003; den Heijer et al., 2003; Raji et al., 2010; Rasgon et al., 2011; Tan et al., 
2011; Tiehuis et al., 2008; Willette et al., 2013), orbitofrontal cortex (Raji et al., 
2010), and prefrontal cortex (Benedict et al., 2012), compared to non-diabetics. In 
addition, longitudinal studies have found that DM patients have greater declines in 
volume, which are associated with cognitive decline; further, these volumetric and 
cognitive performance declines are comparable to three to five years of aging (de 
Bresser et al., 2010; Kooistra et al., 2013; van Elderen et al., 2010).  
While the extent to which DM affects white matter volume is unclear, studies 
have found that DM is associated with declining white matter volumes and 
increasing presence of infarcts, which are linked with cognitive decline (Manschot et 
al., 2006; Reijmer et al., 2011; Saczynski et al., 2009). In the Women’s Health 
Initiative Memory Study cohort, women with DM had significantly more total grey 
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matter volume atrophy, as well as focused grey matter volume loss in the parietal 
and temporal lobes, and larger ventricles and greater ischemic load as compared to 
women without DM (Espeland et al., 2013). Further, it seems that duration and 
severity of DM affects brain volume. Those who have had DM longer have reduced 
grey and white matter, and a greater number of white matter lesions (Saczynski et 
al., 2009). Similarly, diabetics who took medications or insulin (which can be 
considered a marker for more severe DM), have reduced grey and white matter as 
compared to DM patients who did not need to take these medications (Saczynski et 
al., 2009) 
Studies that have examined connectivity in the brains of DM patients have found 
that they have decreased connectivity both locally and globally (Reijmer, Leemans, 
Brundel, Kappelle, & Biessels, 2013), and studies have shown that DM patients have 
reduced functional connectivity between regions of the default mode network 
(Musen et al., 2012). Further, even persons with increased insulin levels have 
decreased functional connectivity in areas associated with cognitive function, 
specifically between the medial prefrontal cortex and hippocampus (Kenna et al., 
2013). These findings indicate that DM patients have both disrupted structural and 
functional connectivity. Insulin resistance has also been linked with impaired Aβ 
clearance and tau phosphorylation, which are thought to contribute to the 
development of the plaques and tangles characteristic of AD (Cholerton, Baker, & 
Craft, 2013; Cook et al., 2003; Farris et al., 2003; Ho et al., 2004; Mayeux et al., 2003; 
Neumann et al., 2008; Perez, Morelli, Cresto, & Castano, 2000). This body of 
evidence suggests that prolonged hyperglycemia and hyperinsulinemia contribute 
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to the pathological development of dementia, and the longer a person has these 
conditions the greater the risk for negative cognitive outcomes becomes.  
Diabetes, APOE and TOMM40, and decline 
The risk relationship between DM and cognitive decline and AD may be 
impacted by APOE and TOMM40, such that diabetics with either an ε4 allele or the 
TOMM40 long allele are at an even greater risk of developing cognitive decline and 
AD compared to those with just one of these risk factors. Studies have found that ε4 
and DM have a synergistic relationship, such that those with both are 5.5 times more 
likely to have AD whereas those with just DM and without an ε4 allele are 1.8 times 
more likely to have AD and those with an ε4 allele without DM are approximately 
twice as like to have AD (Haan, Shemanski, Jagust, Manolio, & Kuller, 1999; Peila et 
al., 2002). However, these risk associations vary by study; a recent meta-analysis 
examined the interaction between DM and APOE on clinical AD, and found that risk 
rates ranged from 1.44 to 4.99 times increased risk (Vagelatos & Eslick, 2013). 
Autopsy studies have also supported this interaction. The brains of diabetics with an 
ε4 allele have more plaques in the hippocampus and tangles in the cortex, compared 
to those of individuals with just one of these risk factors (Peila et al., 2002). It seems 
that hyperglycemia, hyperinsulinemia, and insulin resistance support the formation 
of plaques (Matsuzaki et al., 2010) particularly in those with an ε4 allele. Studies 
have also examined the relationship between insulin resistance and ε4 and risk of 
AD. Two community-based studies have found that impaired insulin function at 
midlife interacted with ε4 to increase risk of AD (Ronnemaa et al., 2008; W. L. Xu, 
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Qiu, Wahlin, Winblad, & Fratiglioni, 2004); however, these findings have not been 
reported consistently (Schrijvers et al., 2010; W. Xu, Qiu, Winblad, & Fratiglioni, 
2007).  
When considering the risk relationship between cerebrovascular and/or 
metabolic conditions (e.g., DM), there is reason to believe that TOMM40, because it 
affects mitochondrial function, modifies this relationship (Hayden et al., 2012; 
Potkin et al., 2009). Multiple studies have found a decreased number of 
mitochondria and decreased brain glucose metabolism early in the AD course (Hirai 
et al., 2001; Mosconi, 2005). Fluoro-2-deoxy-D-glucose positron emission 
tomography (FDG-PET) imaging studies have even shown that there is decreased 
glucose metabolism in areas commonly affected early in the AD process, specifically 
the parieto-tempral and posterior cingulate cortices, as well as the frontal cortex, 
which is affected later in the course of AD (Mosconi, 2005). A recent study has found 
that older diabetics with the VL/VL genotype exhibit poorer cognitive performance, 
compared to those with the S/S genotype (Greenbaum et al., 2014). While it is still 
unclear exactly how TOMM40 may interact with DM to affect risk of dementia and 
cognitive decline, it may prove to be an important modifier because of its role in 
mitochondrial functioning and evidence showing it increases risk of AD.  
Mechanisms 
As previously mentioned, prolonged hyperglycemia and hyperinsulinemia 
may contribute to the development of AD decades prior to clinical onset (Launer, 
2005; Roberts, Knopman, Cha, et al., 2014; W. Xu et al., 2009); however, several 
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other mechanisms may link DM to dementia and cognitive decline. 
Hyperinsulinemia may be detrimental to the otherwise positive effects normal 
levels of insulin have on cognition (Cholerton et al., 2013). Impaired insulin receptor 
signaling is a substantial component of the pathophysiology of both DM and AD 
(Balaraman, Limaye, Levey, & Srinivasan, 2006; Lee & Kim, 2007). Studies in mouse 
models have shown that disrupted insulin signaling increases levels of 
hyperphosphorylated tau and decreases cognitive function (Lucas et al., 2001). It 
has also been found that insulin works to regulate neurotransmitter release and 
synaptic plasticity (Ahmadian et al., 2004; Jonas et al., 1997; Skeberdis, Lan, Zheng, 
Zukin, & Bennett, 2001; Wan et al., 1997; Wang & Linden, 2000). Further, insulin 
receptors are concentrated in the hippocampus and medial frontal cortex, 
suggesting that chronically high levels of insulin might readily affect memory 
(Cholerton, Baker, & Craft, 2011; Craft, 2006; Zhao & Alkon, 2001). Animal studies 
have shown that long-term cognitive impairment results when insulin is depleted in 
mouse model brains, and that this impairment may be prevented if the animals are 
given insulin treatment (Biessels et al., 1998; Grunblatt, Salkovic-Petrisic, 
Osmanovic, Riederer, & Hoyer, 2007; Lannert & Hoyer, 1998). Hyperglycemia and 
hyperinsulinemia have also been shown to downregulate the actions of insulin-
degrading enzyme (IDE) (Cholerton et al., 2013). Downregulation of IDE is 
associated with the formation of neuritic plaques and neurofibrillary tangles, 
through its involvement in Aβ clearance and prevention of tau phosphorylation 
(Alvarez, Munoz, & Maccioni, 2001; Alvarez, Toro, Caceres, & Maccioni, 1999; 
Maccioni, Otth, Conca, & Munoz, 2001; Pandini et al., 2013). In vivo studies suggest 
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that higher levels of insulin in the brain promote the release of Aβ, and may compete 
with Aβ as a target for IDE activity, which hinders breakdown of Aβ (Gasparini et al., 
2001; Watson et al., 2003). 
Advanced glycation end products (AGES) have also been identified as a 
possible mechanism linking DM and AD (Launer, 2005). Both diabetics and AD 
patients have an increased number of AGES compared to normal controls, and AGES 
are at the root of many diabetes complications (e.g., neuropathy, vision loss) (Goh & 
Cooper, 2008; M. A. Smith et al., 1994; Vitek et al., 1994). An increased number of 
AGES is associated with oxidative stress, endothelial and vascular dysfunction, 
increased inflammation, and increased protein, DNA, and mitochondrial damage 
(Mosconi, 2005; Singh, Barden, Mori, & Beilin, 2001). As previously mentioned, 
mitochondrial damage has been found to occur very early in the AD process. Studies 
have also found that in the brains of AD patients, AGES co-localize with apoE, which 
points towards involvement in the formation of neuritic plaques (Y. M. Li & Dickson, 
1997). Additionally, a hormone known as insulinotropic glucagon-like pedptide-1 
(GLP-1), which enables insulin release in hyperglycemic states, reacts in 
hyperglycemic conditions by improving insulin signaling, and, like AGES, defends 
against oxidative stress and neurotoxicity (Holscher, 2010). This suggests that GLP-
1 may also play a role in the risk relationship between DM and AD. Studies have 
found that treatment with GLP-1 may improve cognition and amyloid burden in 
both animals and humans (Bomfim et al., 2012; Sivertsen, Rosenmeier, Holst, & 
Vilsboll, 2012). This evidence suggests that in DM patients metabolic control may be 
a therapeutic target for reducing risk of cognitive decline and dementia.  
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 Oxidative stress and mitochondrial dysfunction are also implicated in the 
relationship between DM and AD. In mouse models, mitochondrial dysfunction 
occurs before plaques and tangles are present, perhaps suggesting that it is a causal 
factor in AD pathogenesis (Chou et al., 2011). Additionally, oxidative stress, which is 
pervasive in both DM and AD patients (Nunomura et al., 2004; Rosen et al., 2001), 
contributes to mitochondrial dysfunction. Oxidative stress promotes Aβ production, 
the Aβ then interacts with mitochondrial proteins, which causes a disruption in the 
electron transport chain, thereby promoting mitochondrial dysfunction and 
production of reactive oxygen species (Oda, Tamaoka, & Araki, 2010; Reddy et al., 
2010) 
 It is likely that mitochondrial dysfunction is the link between DM, genetic 
factors, and AD, as well. As discussed, the APOE- ε4 allele is associated with greater 
risk of AD. Studies have also shown that individuals with an ε4 allele have increased 
mitochondrial dysfunction, which is thought to be caused specifically by ε4 
fragments (Gibson et al., 2000), leading to neuronal damage (S. Chang et al., 2005; H. 
K. Chen et al., 2012). Because TOMM40 affects mitochondrial function, and because 
it appears mitochondria are involved even in the early stages of AD development, 
TOMM40 may also affect the risk relationship between DM and AD (Hayden et al., 
2012; Potkin et al., 2009).  
 Psychiatric and medical conditions may act as mediators or confounders in 
the relationship between DM and AD. For example, major depression is associated 
with both DM and AD, and may act as a major confounder in the risk relationship 
 21 
 
(Stewart & Liolitsa, 1999). Additionally, vascular conditions (e.g., hypertension, 
stroke, and obesity) are often co-morbid with DM, and even pre-date onset of DM in 
many patients.  Because these conditions may contribute to AD, they may be 
confounding observed associations between DM and AD (Stewart & Liolitsa, 1999).  
Potential for Treatment and Prevention 
 Unfortunately, AD treatment efforts, including nonsteroidal anti-
inflammatory drugs (NSAIDs), γ-secretase inhibitors, β-secretase inhibitors, and an 
Aβ binding agent, tramiprosate have been largely unsuccessful to this point 
(Arvanitakis, Bennett, Wilson, & Barnes, 2010; D'Onofrio et al., 2012; Fourrier, 
Letenneur, Begaud, & Dartigues, 1996; Henley, May, Dean, & Siemers, 2009; Kaether, 
Haass, & Steiner, 2006; Morihara, Chu, Ubeda, Beech, & Cole, 2002; Mullard, 2012; 
Szekely, Green, & Breitner, 2008; Wolfe, 2012; Zandi et al., 2002). Some studies have 
suggested that treatment may only be effective prior to Aβ deposition (Lambracht-
Washington & Rosenberg, 2013). Currently, there is no reliable biomarker that 
precedes Aβ deposition that can be used to determine the risk of developing AD 
(Jack et al., 2013). Given these limitations, it may be most effective to focus 
treatment and prevention efforts on persons with known modifiable risk factors, 
such as DM (Kravitz, Schmeidler, & Schnaider Beeri, 2013).  
AD pathology begins to manifest in the brain years or decades prior to 
clinical symptoms become apparent (Amieva et al., 2008; Braak, Thal, 
Ghebremedhin, & Del Tredici, 2011; Jorm, Korten, & Henderson, 1987; Ohm, Muller, 
Braak, & Bohl, 1995). Therefore, introducing interventions in middle age, during or 
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just prior to the prodromal stage of AD, may be the most effective route for slowing 
the progression, delaying onset, or even preventing the disease (Carlson et al., 2008; 
C. Y. Chang & Silverman, 2004). DM is an example of a mid-life modifiable risk factor, 
and it is highly prevalent, so it may be a promising target for altering the course of 
AD (Kravitz et al., 2013). Indeed, diabetics that have received aggressive treatment 
for hyperinsulinemia and blood glucose control showed improvements in cognitive 
performance (Naor, Steingruber, Westhoff, Schottenfeld-Naor, & Gries, 1997; Ryan 
et al., 2006). In the ACCORD-MIND study cohort, the rate of brain atrophy on 
repeated MRI scans was slowed in DM patients who received intensive glycemic 
control treatment compared to patients who received standard treatment; however, 
these volumetric differences were not associated with improved cognitive function 
(Launer et al., 2011).  
Similarly, treating dementia patients and those with cognitive impairment 
with intranasal insulin and rosiglitazone has been shown to improve cognitive 
function in these populations. (Craft et al., 2003; Craft et al., 1999; Craft et al., 1996; 
Craft et al., 1998; Park, Seeley, Craft, & Woods, 2000; Risner et al., 2006). Recent 
clinical trials investigating the potential benefits of the common type II diabetes oral 
medication pioglitazone have found that adults over age 60 taking the drug reduced 
their risk of developing AD by 6 percent; however, more extensive clinical trials are 
needed to determine the potential benefits of the drug (German Center for 
Neurodegenerative Diseases, 2014). Thus, DM pharmaceuticals may work to alter 
the course of AD in both diabetics and cognitively impaired individuals. Nonetheless, 
some studies have found that these treatments may not be effective in ε4 allele 
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carriers (Craft et al., 2003; Reger et al., 2008). Further studies are needed to 
understand the association between DM and cognitive decline, and how genetics 
impact this relationship. Such studies will help identify therapeutic targets for 






PUBLIC HEALTH SIGNIFICANCE  
 Given the high and increasing prevalence of both DM and AD, and the myriad 
negative outcomes associated with both diseases, it is becoming increasingly 
important to find ways to treat and prevent DM and AD. Although DM is associated 
with an increased risk of AD (Vagelatos & Eslick, 2013), the nature and mechanisms 
of this risk relationship are still unconfirmed. Using population attributable risk 
analyses, one study found that approximately 30 percent of AD cases are 
attributable to modifiable risk factors (Barnes & Yaffe, 2011). The authors proposed 
that interventions at mid-life that target these factors, including vascular and 
metabolic variables (e.g., physical inactivity, smoking, hypertension, obesity, and 
diabetes), may reduce the prevalence of AD (Norton et al., 2014). The research 
presented here investigates DM as a risk factor for cognitive decline, AD or MCI 
symptom onset, and grey matter atrophy, and genetic factors that may affect these 
risk relationships in a sample at high-risk of developing AD. Prior studies indicate 
that individuals with both DM or pre-diabetes and a genetic risk factor are at 
elevated risk for developing AD or MCI, will have steeper trajectories of cognitive 
decline, and greater brain atrophy in areas associated with AD, as compared to 
individuals with one or neither of these risk factors, (Benedict et al., 2012; Chartier-
Harlin et al., 1994; Peila et al., 2002; Potkin et al., 2009; Raji et al., 2010; Schanider 
Beeri et al., 2004; Shen et al., 2010). This research aims to elucidate the role of DM 
and genetic factors in the progression of AD, from the prodromal phase to clinical 
onset (Amieva et al., 2008; Braak et al., 2011).  
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 Results of this research may have implications for future treatment targets 
and intervention strategies. In light of the epidemic levels of DM and increasing 
prevalence of AD, and the apparent connection between the two diseases, it is 
essential to understand the relationship between the diseases and how this link may 
be leveraged to alter the course and prevalence of AD. Because pharmacological 
treatments of AD have been largely unsuccessful, targeting modifiable risk factors 
may be the most promising route for altering the course of, delaying the onset of, or 
even preventing AD (Craft et al., 2003; Giacobini & Gold, 2013; Kravitz et al., 2013). 
Further, genotyping is becoming more accessible and affordable, so it is becoming 
easier to identify individuals who are at heightened risk of cognitive outcomes, 
based both on their genotype and lifestyle risk factors. Therefore, if the hypotheses 
guiding this research are supported, clinicians may be able to design treatment 
strategies, including tighter metabolic control in DM patients, and other individuals 
at increased risk based on these risk factors. This would have implications for 
reducing the prevalence of AD, and subsequently reducing the healthcare costs of 





DATA: THE BIOCARD COHORT 
This study used data from the Biomarkers of Cognitive Decline Among 
Normal Individuals (BIOCARD) cohort. The BIOCARD study began at the National 
Institutes of Health (NIH) in 1995; it was discontinued in 2005 due to 
administrative reasons. The study was re-initiated 2009 at the Johns Hopkins 
University School of Medicine via a U01 mechanism (PI: Marilyn Albert, PhD). The 
study initially enrolled and followed 349 participants; they were mainly middle-
aged and all were cognitively normal. The cohort was considered at high-risk of 
developing dementia as nearly 75 percent of participants had a first-degree relative 
with dementia. Approximately half of the participants were female, the majority of 
participants were White, and they were, on average, highly educated (Table 1). 
Participants were recruited via local and national advertisements, word-of-mouth, 
and educational lectures. Exclusion criteria included significant cognitive 
impairment (e.g., dementia, MCI), or presence of significant medical, physical, 
psychiatric or neurological disorders (e.g., severe cardiovascular disease, 
schizophrenia, or seizure disorders), which was based on a clinical exam (Moghekar 
et al., 2013; Soldan et al., 2013). Presently, 89 percent of the initial cohort have been 
reenrolled; 38 participants are now deceased. On average, participants have been 
followed for 12.2 years (range 8 to 18 years). BIOCARD was designed to identify risk 
factors for dementia and to study the prodromal stages of dementia. Since re-
initiation, the study is analyzing existing data, and is continuing to collect data from 
enrolled participants; it is not enrolling any new participants.  
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Participants completed a two-day comprehensive exam, including a physical 
and neurological exam, a neuropsychological battery, structural magnetic resonance 
imaging (MRI), and standard blood work (e.g., complete blood count, cholesterol 
count, B12 levels), at the Clinical Center of the NIH at enrollment. A subset of 
participants also consented to have their cerebrospinal fluid (CSF) drawn via 
lumbar puncture; 307 participants had their CSF drawn once, and 199 participants 
had their CSF drawn more than once (Moghekar, Goh, Li, Albert, & O'Brien, 2012). 
During the annual follow-up appointments between 1995 and 2005, BIOCARD 
participants completed the neuropsychological battery, and a physical and 
neurological exam. Every other year, participants completed MRI scans, blood work, 
and CSF draws (if consented) (Figure 1). Since re-initiation at Johns Hopkins 
University in 2009, annual exams have included a physical and neurological exam; 
assessment of past and present medication use; mood assessment with the Geriatric 
Depression Scale (Yesavage et al., 1982); assessment of family history of dementia; a 
similar neuropsychological assessment; and history of clinical symptom onset based 
on participant and informant reports (e.g., a family member) derived from the 








measures (range 1 to 7) per participant.  
Neuropsychological Battery 
 From 1995 to 2005, and from 2009 to present, BIOCARD participants have 
completed a neuropsychological battery annually. The battery includes tests that 
measure a range of cognitive domains (i.e., memory executive function, language, 
visuospatial ability, attention, speed of processing, and psychomotor speed). The 
tests include the Mini-Mental State Exam (Folstein, Folstein, & McHugh, 1975), 
Letter and Category Fluency (Brenton & Hamsher, 1976), the Boston Naming Test 
(30-item version) (Kaplan, Goodglass, & Weintraub, 1983), the Logical Memory and 
Paired Associates subtests from the Wechsler Memory Scale – Revised (Wechsler, 
1987), the California Verbal Learning Test (Delis, Kramer, Kaplan, & Ober, 1987), 
the Digit Span Backward and Forwards tests from the Wechsler Memory Scale – 
Revised (Wechsler, 1987), the Rey-Osterreith Figure, copy and recall (Rey, 1941), 
the Trail Making Test, Parts A and B (Reitan, 1958), the Block Design subtest of the 
Wechsler Adult Intelligence Scale – Revised (Wechsler, 1981), the Digit Symbol 
Substitution Test from the Wechsler Adult Intelligence Scale – Revised (Wechsler, 
1981), and the Grooved Pegboard test (Klove, 1963).  
 On average, participants have completed at least a partial portion of the 
battery a mean of 7.3 assessments each. In total, 2,029 follow-up assessments have 
been completed. Since 2009, when the study was moved to Johns Hopkins 
University, the battery was shortened slightly due to time constraints.  
AD and MCI consensus diagnosis  
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 The BIOCARD Clinical Core at Johns Hopkins University performs an annual 
consensus diagnosis for each participant. The Clinical Core is comprised of 
neurologists, neuropsychologists research nurses, and research assistants. For each 
participant, the team considers changes in performance on the BIOCARD 
neuropsychological battery, reports from the participant and informant (e.g., a 
family member) regarding changes in cognition using the CDR, and other relevant 
clinical data in order to determine if the participant has MCI or dementia, or is 
cognitively normal. If a participant is diagnosed with MCI or dementia, the team also 
determines the age of onset and the cause of the impairment (e.g., Parkinson’s 
disease, AD, or vascular dementia). This diagnostic method has been applied 
posthumously to the 38 deceased participants. To date, 49 participants have been 
diagnosed with MCI, and 14 participants have been diagnosed with AD. This 
research only included participants with late-onset or sporadic, as opposed to early-
onset or familial AD and MCI in the analyses (Albert et al., 2013).  
MRI Scans 
 MRI images were obtained using a 1.5 Tesla General Electric scanner. The 
scanning protocol involved localizer scans, axial Fast Spin Echo sequence (TR = 
4250, TE = 108, FOV = 512 × 512, thickness/gap = 5.0/0.0 mm, flip angle = 90, 28 
slices), Axial Flair sequence (TR = 9002, TE = 157.5, FOV = 256 × 256, thickness/gap 
= 5.0/0.0 mm, flip angle = 90, 28 slices), Coronal Spoiled Gradient Echo sequence 
(TR=24, TE- 2 FOV = 256 × 256, thickness/gap = 2.0/0.0 mm, flip angle = 20, 124 
slices), and Sagittal Spoiled Gradient Echo sequence (TR = 24, TE = 3, FOV = 256 × 
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256, thickness/gap = 1.5/0.0 mm, flip angle = 45, 124 slices) (Miller et al., 2013). As 
described by Miller and colleagues, the analysis of the scans focused on measuring 
the volume and thickness of the hippocampus, entorhinal cortex, and amygdala 
(Miller et al., 2013). The BIOCARD imaging core used the process of 
diffeomorphometry to analyze the scans (Csernansky et al., 2000; Qiu, Crocetti, et al., 
2009; Qiu, Fennema-Notestine, Dale, & Miller, 2009). Diffeomorphometry consists of 
three steps: 1) segmentation of the target structures; 2) creation of a single template 
coordinate system from the baseline scan; and 3) mapping the template onto the 
target structure using triangulated meshes. Intracranial volume was calculated 
using coronal SPGR scans in FreeSurfer 5.1.0 (Segonne et al., 2004); the 
aforementioned structures were compared against intracranial volume in order to 
normalize specific structure volumes.  
Additionally, cortical thickness in AD-signature regions was calculated with 
FreeSurfer. AD signature regions, as identified by Dickerson and colleagues (2009; 
2011), include the entorhinal cortex, inferior temporal gyrus, parahippocampal 
gyrus, pars triangularis of the inferior frontal gyrus, precuneus, superior frontal 
gyrus, superior parietal gyrus, supramarginal gyrus, and temporal pole. Cortical 
thickness was measured using MRI scans, and by calculating the space from the 
boundary of grey matter and white matter to the boundary between grey matter 
and CSF (Fischl & Dale, 2000); the measures were based on both spatial intensity 
gradients and signal intensity. This method of measurement tessellates the 
boundary between grey and white matter, uses automated topology correction 
(Fischl, Liu, & Dale, 2001; Segonne, Pacheco, & Fischl, 2007), and accounts for 
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surface deformation (Dale, Fischl, & Sereno, 1999; Dale & Sereno, 1993; Fischl & 
Dale, 2000). This method of measurement has good validity and reliability (Han et 
al., 2006; Kuperberg et al., 2003; Rosas et al., 2002; Salat et al., 2004). Participants 
completed scans every other year, on average, while the study was being conducted 
at the NIH (1995 to 2005). There were 335 participants who underwent an MRI 





STATEMENT OF STUDY AIMS 
This study aims to elucidate the relationship between glucose and AD and 
cognitive outcomes, and how genetic risk factors affect this risk relationship, in a 
sample that is considered high-risk for developing dementia. In particular, this 
study investigated how baseline glucose levels were associated with cognitive test 
performance over time, time to dementia or MCI symptom onset, and cortical 
thickness measures at baseline. Additionally, it investigated how the APOE ε4 allele 
and TOMM40 genotype may modify the relationship between glucose and these 
outcomes. The TOMM40 analyses were restricted in order to be sufficiently 
conservative in their assumptions. Specifically, these analyses were limited to 
subjects who were ε3 homozygous. This was done because the S allele may have a 
negative impact on cognitive outcomes in ε3/4 carriers (Gold, Johnson, Powell, & 
Smith, 2012; Gold, Powell, Andersen, & Smith, 2010; Greenbaum et al., 2014; Lyall et 
al., 2014), and this assured that the outcomes were not affected by the presence of 
either the ε4 or ε2 allele (Gold et al., 2012; Gold et al., 2010; Greenbaum et al., 2014; 
Lyall et al., 2014). Further, this study only compared VL homozygotes to S 
homozygotes, because the L allele is in high linkage disequilibrium with the ε4 allele 
(Greenbaum et al., 2014).  Finally, all TOMM40 interaction analyses were restricted 
on only Caucasian participants, because TOMM40 poly-T length and associated risk 
with dementia and cognitive performance outcomes varies by race and ethnic group 
(Roses et al., 2014). This study was conducted using data from participants in the 
BIOCARD Study. The aims of this thesis were as follows: 
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Aim 1  
To examine the association between baseline glucose and time to onset of MCI 
or dementia symptoms, cognitive test performance over time, and cortical 
thickness in AD-signature regions at baseline. 
Hypothesis 1a. Higher baseline glucose will be associated with greater risk of and 
earlier onset of MCI or dementia symptoms. 
Hypothesis 1b. Higher baseline glucose will be associated with declining performance 
on a battery of cognitive tests over time. 
Hypothesis 1c. Higher baseline glucose will be associated with reduced cortical 
thickness measures in AD-signature regions (i.e., entorhinal cortex, inferior  temporal 
gyrus, parahippocampal gyrus pars triangularis, precuneus, superior frontal and 
parietal gyri, supramarginal gyrus, and temporal pole) at baseline. 
Aim 2 
To examine the interaction of baseline glucose level with APOE and TOMM40 
genotypes on cognitive decline, as measured by a battery of 
neuropsychological tests. 
Hypothesis 2a. The APOE-ε4 allele and glucose level will interact, such that the 
association between glucose and poorer cognitive performance over time is stronger 
among those with an APOE- ε4 allele than among those without. 
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Hypothesis 2b. The TOMM40 VL/VL genotype and glucose level will interact, such that 
the association between glucose and both poorer cognitive performance over time is 
stronger among those with the TOMM40 VL/VL genotype than among those with the 
TOMM40 S/S genotype. 
Aim 3  
To examine the interaction of baseline glucose level with APOE and TOMM40 
genotypes on time to dementia or MCI symptom onset.  
Hypothesis 3a. The APOE-ε4 allele and glucose will interact, such that the association 
between glucose level and dementia or MCI symptom onset is stronger among those 
with an APOE-ε4 allele than among those without.  
Hypothesis 3b. The TOMM40 VL/VL genotype and glucose will interact, such that the 
association between glucose level and dementia or MCI symptom onset is stronger 
among those with the TOMM40 VL/VL genotype than among those with the TOMM40 
S/S genotype. 
Aim 4 
To examine the interaction of APOE and TOMM40 genotypes with glucose 
level on cortical thickness measures in AD-signature regions at baseline. 
Hypothesis 4a. The APOE-ε4 allele and glucose will interact such that higher glucose 
levels will be more strongly associated with thinner cortical measures among those 
with an APOE-ε4 allele than among those without. 
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Hypothesis 4b. The TOMM40 VL/VL genotype and glucose will interact such that 
higher glucose levels will be more strongly associated with thinner cortical measures 







Baseline blood glucose and genetic factors as predictors of 
cognitive decline 
ABSTRACT 
Type II diabetes mellitus (DM) has been associated with cognitive decline. There 
may be an interaction between DM and the apolipoprotein E (APOE) ε4 allele, such 
that those with both are at greater risk for cognitive decline. There may be a similar 
relationship between DM and the translocase of the outer mitochondrial membrane 
(TOMM) 40 very long (VL) homozygous genotype with respect to cognitive 
performance, whereas short (S) homozygotes may be protected. Here, we 
investigated the association between baseline fasting blood glucose level and 
cognitive test performance over time in 333 participants from the BIOCARD Study, a 
cognitively healthy, middle-aged cohort. Glucose level was measured at the baseline 
clinical exam. We used confirmatory factor analysis (CFA) to generate latent 
variables measuring executive function and memory based on a battery of 
neuropsychological tests. We found that higher baseline blood glucose was 
associated with declining executive function using linear mixed effects models 
(LMM) (B=-0.005; 95% CI -0.008, -0.001) and generalized estimating equation 
(GEE) models (B=-0.004; 95% CI -0.007, -0.001) adjusted for sex, age, education, 
depression, and medical conditions. This association was stronger amongst ε4 
carriers (B=-0.013; 95% CI -0.020, -0.006), versus non-carriers (B=-0.002, 95% CI -
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0.006, 0.002). In LMMs, glucose was associated with declining executive function 
factor score in subjects with the S/S genotype (B=-0.013; 95% CI -0.024, -0.002), 
versus the VL/VL genotype (B=0.004; 95% CI -0.003, 0.010). Findings suggest that 
glucose control is important for maintaining cognitive function over time, even in 

















 Type II diabetes mellitus (DM) and pre-diabetes affect approximately half of 
the older adults in the United States (American Diabetes Association, 2014b). DM is 
associated with a number of negative physical and mental health outcomes (e.g., 
neuropathy, kidney problems, depression) (American Diabetes Association, 2014b), 
and there is broad empirical evidence that DM is also associated with greater age-
related cognitive decline in multiple cognitive domains (Cukierman et al., 2005; 
Schrijvers et al., 2010; Tan et al., 2011). Epidemiological studies in large national 
cohorts have found that DM is associated with poorer performance on memory and 
visuospatial tasks (Elias et al., 1997; Wennberg et al., 2014). Recent studies have 
also found that DM and higher insulin and blood sugar levels are associated with 
poorer performance on tasks measuring global cognition, memory, speed of 
processing, verbal fluency, attention and working memory, and executive function 
(Burns et al., 2012; Lamport et al., 2009; West et al., 2014). Further, evidence 
suggests that longer duration of DM or poor glycemic control is associated with 
greater cognitive deficits and faster decline (Rawlings et al., 2014; Roberts, 
Knopman, Przybelski, et al., 2014; West et al., 2014). It also appears that cognitive 
decline associated with insulin resistance and higher glucose levels begins during 
the prediabetic stage in later midlife (i.e., 55 to 65 years of age), and that the 
greatest amount of damage due to insulin resistance and disrupted glucose levels 
occurs prior to diagnosis of AD (Biessels et al., 2014; Tuligenga et al., 2014). 
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 The apolipoprotein-E (APOE) ε4 allele has been established as a risk factor 
for AD and associated cognitive decline; many studies have shown that carriers of 
the ε4 allele are at greater risk of both of these outcomes (Chartier-Harlin et al., 
1994; Mormino et al., 2014). There is also evidence that there may be a synergistic 
relationship between DM and the APOE ε4 allele, such that individuals who have 
both DM and an ε4 allele are more likely to develop AD and experience greater 
atrophy in brain areas associated with cognition and more neuritic plaques in the 
hippocampus and neurofibrillary tangles in the cortex compared to those with 
either DM or an ε4 allele (den Heijer et al., 2003; Peila et al., 2002). It has also been 
shown that both MCI patients and cognitively normal individuals who have both DM 
and an ε4 allele have faster cognitive decline and poorer performance on memory 
tasks (Caselli et al., 2007; Caselli et al., 2004; Cosentino et al., 2008; Farlow et al., 
2004; Ravona-Springer et al., 2014; Whitehair et al., 2010).  
Similarly, pathophysiological evidence suggests that there may be a similar 
relationship between DM and the translocase of the outer mitochondrial membrane 
(TOMM) 40 gene (Caspersen et al., 2005; Hansson Petersen et al., 2008). TOMM40 
has three allelic variations – short (S), long (L), and very long (VL). The number of 
poly-T repeats in the chromosome determines allele length. Longer poly-T repeats 
(i.e., ≥ 27) have been found to be associated with risk of AD and earlier onset of AD, 
while shorter poly-T repeats (i.e., ≤ 16 repeats) may be protective (Abraham et al., 
2008; Grupe et al., 2007; Harold et al., 2009; G. Li et al., 2013; Roses et al., 2010). 
Studies have found that carriers of the TOMM40 VL allele have an increased risk of 
AD; this is the case in both those who carry just one VL allele (odds ratio = 2.96), and 
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in those who carry two VL alleles (odds ratio = 5.66) (G. Li et al., 2013). Further, the 
VL allele has also been associated with increased risk of MCI and hippocampal 
atrophy (Potkin et al., 2009; Shen et al., 2010). Given this evidence, and the 
aforementioned risk association of APOE ε4 and DM with cognitive outcomes, it is 
reasonable to believe that the TOMM40 VL/VL genotype modifies the relationship 
between DM and cognitive performance.  
The current study investigated the association between DM and cognitive 
performance using participants in a study known as the Biomarkers of Cognitive 
Decline Among Normal Individuals: the BIOCARD cohort. We hypothesized that 
higher baseline blood glucose levels would be associated with declining 
performance on neuropsychological tests over time. Further, we hypothesized that 
those with both higher glucose and an ε4 allele or higher glucose and a TOMM40 
long allele would have even greater cognitive decline. 
METHODS 
BIOCARD Study  
 In 1995 the BIOCARD Study began at the National Institutes of Health (NIH). 
It was discontinued in 2005 due to administrative reasons, but was re-initiated at 
the Johns Hopkins University School of Medicine in 2009 (PI: Marilyn Albert, PhD). 
At the NIH, 349 participants were enrolled in the study. Since re-initiation, 89 
percent of the original participants have been reenrolled; 38 participants are 
deceased. The primary goal of the study was to identify risk factors for cognitive 
impairment and dementia in a mainly middle-aged, high-risk cohort. The sample 
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was characterized as such because participants were recruited based on family 
history of dementia; nearly three-quarters had a first-degree relative with dementia. 
The goal of the ongoing research at Johns Hopkins is to analyze existing data, and to 
continue to collect data from participants without enrolling new participants 
(Moghekar et al., 2013; Soldan et al., 2013).  
When participants were enrolled at the NIH, they underwent a two-day 
comprehensive exam that included a physical and neurological assessment, a 
neuropsychological battery, structural magnetic resonance imaging (MRI), and 
blood draw with common lab assays (e.g., glucose, albumin, creatinine). A subset of 
participants also volunteered to have their cerebrospinal fluid (CSF) collected via 
lumbar puncture (Moghekar et al., 2012). Participants had annual follow-up visits; 
at each visit participants underwent a clinical and neurological exam, as well as a 
neuropsychological battery. While the study was conducted at the NIH, participants 
completed MRI scans, CSF draws, and blood draws every other year.  
Participants 
Participants were excluded from the BIOCARD Study if they presented with 
any significant cognitive impairment, or medical, psychological, or neurological 
disorder (e.g., severe cardiovascular disease, schizophrenia, or seizure disorder).  
Participants were mostly middle aged at recruitment. The sample is a high-risk 
sample for dementia, as approximately three-quarters of participants had a first-
degree relative with dementia. This analysis included 333 participants from the 
BIOCARD Study. Informed consent was obtained from all participants.  
 43 
 
Glucose and Diabetes Measures 
 Fasting blood glucose was collected during routine blood draws at the 
BIOCARD clinical appointments. In some instances, blood glucose was collected 
more frequently (e.g., for participants enrolled in different studies, at routine 
medical appointments, etc.), and these data were also included in our analysis. Of 
the 349 participants, 333 had baseline blood glucose data. During the clinical exam, 
it was also determined if the participant had a history of DM, and if they were using 
any medications (e.g., insulin, Metformin) to manage their DM. 
Genotyping 
 Participant’s APOE genotype was determined using blood samples collected 
at the NIA. TOMM40 genotype was determined using blood samples collected at 
Johns Hopkins University.  Genotyping was performed using restriction 
endonuclease digestion of polymerase chain reaction amplified genomic DNA; this 
was completed by Athena Diagnostics (Worcester, MA). For statistical analyses, we 
coded participants with one or more ε4 alleles as ‘1,’ and those without were coded 
as ‘0.’ Participants with the TOMM40 VL/VL genotype were also coded as ‘1,’ while 
those with the S/S genotype were coded as ‘0.’ 
 For the purposes of this study, we restricted the TOMM40 analyses in order 
to take a more conservative approach. Although the S/S genotype is usually 
considered protective, as compared to VL/VL, studies have shown that the S allele 
may confer risk among individuals with an APOE ε3/4 genotype (Gold et al., 2012; 
Gold et al., 2010; Greenbaum et al., 2014; Lyall et al., 2014). Therefore, we restricted 
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analyses to APOE ε3 homozygotes. This also reduced the likelihood that any 
association between glucose and cognition we observed was caused by either the ε2 
or ε4 APOE alleles (Gold et al., 2012; Gold et al., 2010; Greenbaum et al., 2014; Lyall 
et al., 2014). We only compared VL homozygotes to S homozygotes, because the L 
allele is in high linkage disequilibrium with the ε4 allele, and we did not want to 
inadvertently capture any effect of APOE (Greenbaum et al., 2014). Finally, we 
restricted TOMM40 analyses to only include White participants because it is thought 
that, as in APOE, TOMM40 poly-T repeats and associated risk varies by race and 
ethnic group, but these variations are not yet well understood (Roses et al., 2014). 
Cognitive outcomes 
The BIOCARD participants (n=349) completed a battery of 
neuropsychological tests on an annual basis. The tests include the Mini-Mental State 
Exam (Folstein et al., 1975), Letter and Category Fluency (Brenton & Hamsher, 
1976), the Boston Naming Test (30-item version) (Kaplan et al., 1983), the Logical 
Memory and Paired Associates subtests from the Wechsler Memory Scale – Revised 
(Wechsler, 1987), the California Verbal Learning Test (Delis et al., 1987), the Digit 
Span Forward and Backward tests from the Wechsler Memory Scale – Revised 
(Wechsler, 1987), the Rey-Osterreith Figure, copy and recall (Rey, 1941), the Trail 
Making Test, Parts A and B (Reitan, 1958), the Block Design subtest of the Wechsler 
Adult Intelligence Scale – Revised (Wechsler, 1981), the Digit Symbol Substitution 
Test from the Wechsler Adult Intelligence Scale – Revised (Wechsler, 1981), and the 
Grooved Pegboard test (Klove, 1963). Participants completed at least some of the 
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tests at 7.3 visits, on average. All participants completed the battery upon study 
entry, and an additional 2,029 follow-up assessments have been completed.  
Additional Variables 
 Participants also reported their age, the number of years of education they 
completed, and their race (i.e., White, African American, Hispanic, Other). 
Participants were also asked if they had a first-degree relative with dementia, and if 
so, how that relative was related to them (e.g., mother, father, sibling, etc.). During 
the clinical exam, participants were weighed and measured, and this information 
was used to calculate body mass index (BMI; kg/m2). Participants were also asked if  
about their history of medical conditions, including cardiovascular disease, 
cerebrovascular disease, neurological conditions, metabolic conditions, mental 
health conditions (e.g., depression, anxiety), and smoking and substance use history. 
Participants also completed a number of standard clinical tests, a blood panel (e.g., 
cholesterol, potassium, bilirubin, etc.), was performed on drawn blood, and 
participants were asked about past and present medication use.  
Statistical Analysis 
 We used Chi-squared and t-tests to determine if there were any differences 
in participant characteristics by ε4 status or TOMM40 genotype. We used linear 
mixed effects models (LMMs) with an autoregressive correlation matrix and  
generalized estimating equations (GEE) with an unstructured correlation matrix  to 
examine the association between glucose at baseline and cognitive test scores over 
time. We also created interaction terms between glucose and APOE and glucose and 
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TOMM40 to determine the association between the interaction of glucose and ε4 
status and cognitive performance, as well as the association between the interaction 
of glucose and TOMM40 genotype and cognitive performance. A priori to the 
analyses, we decided that if the interaction terms had a p-value ≤ 0.10 we would 
stratify the results.  We chose to use an unstructured correlation matrix in the GEE 
models because when we attempted the analyses using an autoregressive 
correlation matrix, the pattern of missingness caused the model to drop many of the 
observations, greatly diminishing power. Therefore, the results from the GEE 
models may be asymptotically robust due to misspecification of the correlation 
structure. The results examining the association between baseline glucose and 
individual cognitive test scores over time were not robust, so we chose to combine 
the test scores to create more sensitive measures of cognition. We did this with 
confirmatory factor analysis (CFA). 
Confirmatory Factor Analysis 
 CFA is based on structural equation modeling, and factors can be created 
based on a priori hypotheses (Jöreskog, 1969). Based on theory and a priori 
hypotheses, we grouped tests based on the cognitive domain they test (e.g., 
executive function, memory). We used orthogonal rotation, maximum likelihood 
estimation with robust variance estimation to estimate the models, and determined 
which tests loaded to which factors using a cut-off factor loading of 0.4 or greater. 
The number of factors was determined using an Eigenvalue of 1 or greater; this was 
verified using a scree plot. For these analyses, we used two factors. The first we 
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called “executive function,” and it included scores from the Digit Span backward, 
DSST, Verbal Fluency “A,” and WAIS Block Design (Table 2). The second we named 
“memory;” it included scores from Logical Memory immediate and delayed recall 
and Paired Associates learning and delay (Table 3). We used LMMs with 
autoregressive correlation matrices and GEE models with unstructured correlation 
matrices to determine the association between baseline glucose and factor score 
over time. We examined these associations in a model that controlled for age and 
sex (Model 1), and a fully-adjusted model that controlled for age, sex, education, 
race, medical conditions (i.e., cardiovascular disease, hypertension, 
hypercholesterolemia, traumatic brain injury (TBI)), and depression (Model 2). We 
again used interaction terms to determine if the association between glucose and 
factor score was modified by ε4 status or TOMM40 genotype. All analyses were 
completed using Stata 12.0 (StataCorp, 2009 College Station, TX). 
RESULTS 
Participant Characteristics  
 There were 333 participants with a baseline blood glucose measure. Of these, 
58% were female, 98% were White, and they were on average 56.9 years old 
(SD=10.2). They had a high mean level of education (17.1 years, SD=2.4). As would 
be expected, given BIOCARD exclusion criteria, participants were relatively healthy; 
few reported history of or current medical conditions (i.e., cardiovascular disease, 
hypertension, hypercholesterolemia, TBI) (Table 1).  Approximately one-third of 
participants had at least one ε4 allele. Those with an ε4 allele were more likely to 
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have hypercholesterolemia and depression (Table 1). Of the participants who were 
White and were APOE ε3 homozygous, 55 had the TOMM40 VL/VL genotype and 56 
had the S/S genotype; there were no differences in demographic variables between 
the two genotypes (Table 1).  
Association between Glucose and Factor Scores: LMMs 
 In a model that included sex and age as covariates (Model 1), we found that 
higher baseline blood glucose was associated with a declining score on the executive 
function factor (B=-0.004; 95% CI -0.007, -0.0005). This association remained 
significant (B=-0.004; 95% CI -0.008, -0.001) after also controlling for education, 
race, and medical conditions (Model 2). There was no association between baseline 
glucose and memory factor score over time in either Model 1 or Model 2 (Table 4). 
Although there was a significant interaction term (p=0.015) between glucose and 
APOE for the memory factor in Model 2, this was not significant after stratification. 
However, among those with the S/S genotype, higher baseline blood glucose was 
associated with decreasing executive function factor score (B=-0.013; 95% CI -0.024, 
-0.002), as compared to those with the VL/VL genotype (B=0.004; 95% CI -0.003, 
0.010), in a model that controlled for sex and age (p for interaction=0.009) (Table 5). 
There was not an interaction between glucose and TOMM40 genotype in Model 2.  
The Association between Glucose and Factor Scores: GEE Models 
 Similar to results from LMMs, we found that in both Models 1 (B=-0.007; 
95% CI -0.010, -0.004) and 2 (B=-0.004; 95% CI -0.008, -0.001), higher baseline 
blood glucose was associated with declining executive function factor score in GEE 
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models, as well (Table 6). Again, baseline blood glucose was not associated with the 
memory factor in either of the two models. In interaction analyses investigating the 
association between glucose and memory factor, the interaction term between 
glucose and TOMM40 was not significant (p=0.204). The interaction term between 
glucose and TOMM40 for executive function was significant (p=0.015), but this 
association did not remain significant after stratification. Again, there was no 
significant interaction between glucose and TOMM40 in Model 2. However, in the 
fully adjusted model, higher baseline blood glucose was associated with decreasing 
executive function score amongst those with one or more ε4 alleles (B=-0.013; 95% 
CI -0.020, -0.006), as compared to those without an ε4 allele (B=-0.005; 95% CI -
0.009, -0.002) (p for interaction = 0.019) (Table 7). The interaction term was also 
significant (p=0.019) for the memory factor, but associations between glucose and 
the memory factor were not significant after stratification by APOE ε4 status.  
DISCUSSION 
 This study examined the association between baseline blood glucose and 
subsequent change in cognitive performance over time in a middle-aged cohort at 
elevated risk for developing dementia. Higher baseline blood glucose was associated 
with declining executive function factor score. In some analyses, this association 
was stronger among those with one or more APOE ε4 alleles. Additionally, our 
analyses using LMMs indicated that this relationship was more robust among 
TOMM40 S homozygotes. However, analyses using GEE models showed that the 
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interaction between glucose and TOMM40 was only significant for the memory 
factor score.  
 This study used CFA to create latent factors as a means of measuring 
cognitive change. This was done to create a more sensitive measure of cognitive 
domains. However, using these factors makes interpretation of the coefficients more 
difficult. On the executive function factor, most participants had a score between -2 
and 2 (Figure 2). To put this into context, those with a score of -2 on the executive 
function factor had a mean score of 29.8 on the DSST, 6.6 on the verbal fluency test, 
13.4 on the WAIS block design test, and 3.9 on the Digit Span backward test. 
Conversely, those with a score of 2 had mean scores of 87.7 on the DSST, 20.7 on the 
verbal fluency test, 48.8 on the WAIS block design test, and 11.3 on the Digit Span 
backward test. Although our coefficients may seem small, over time a coefficient of -
0.004 is clinically significant. Blood glucose levels tend to increase with age, and can 
have great variation during the aging process. For example, a study in a nationally 
representative cohort found that from the ages of 40 to 70, fasting blood glucose 
increases by 20 mg/dL, on average (Yashin et al., 2009). This translates into 
appreciable decline on the executive function factor (i.e., 20 x -0.004= -0.08), and 
this decline would be even greater for those who experience greater than average 
increases in blood glucose level over time, even if they are never diagnosed with DM.  
These findings are consistent with past studies. It has been found that DM 
patients have 45% faster decline in memory, 29% in reasoning, and 24% in global 
cognition, as compared to normal controls; this translates to 3.3 years aging in 
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memory, 2.9 years in reasoning, and 4.4 years in global cognition (Tuligenga et al., 
2014). A recent study also found that higher glucose in later middle-aged subjects 
without DM was associated with decline in perceptual speed, verbal and spatial 
ability, and global cognition (Seetharaman et al., 2014). It is thought that DM and 
hyperglycemia begins to affect cognition as early as midlife (Tuligenga et al., 2014; 
West et al., 2014). Hyperglycemia damages neurons, produces glutamate toxicity, 
and increases oxidative stress, which produces mitochondrial damage (Nunomura 
et al., 2004; Rosen et al., 2001; West et al., 2014). Studies in animal models show 
that mitochondrial dysfunction occurs prior to plaque and tangle formation, and 
may contribute to AD pathogenesis (Chou et al., 2011). Oxidative stress-induced 
mitochondrial dysfunction caused by hyperglycemia may also be a link between DM, 
genetic factors, and neurocognitive outcomes. Carriers of the ε4 allele have 
increased mitochondrial dysfunction caused by ε4 fragmentation (Gibson et al., 
2000), which causes neuronal damage (S. Chang et al., 2005; H. K. Chen et al., 2012). 
TOMM40 is also linked with mitochondrial and metabolic function, and because 
mitochondrial function is important in the early stages of AD development, 
TOMM40 may also affect the risk relationship between hyperglycemia and cognitive 
decline (Hayden et al., 2012; Potkin et al., 2009). This suggests that elevated glucose 
levels, even in people without a DM diagnosis, may be susceptible to the negative 
impact that hyperglycemia has on cognitive function, and individuals with an ε4 
allele or the TOMM40 VL/VL genotype may be even more vulnerable.  
 The findings of this study must be viewed alongside its limitations. We 
hypothesized that the VL/VL group would have greater decline than the S/S group. 
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This was based on other findings that have shown the VL/VL allele is associated 
with poorer cognitive performance in diabetics (Greenbaum et al., 2014). However, 
we found that subjects with the S/S genotype had declining factor scores over time, 
but we suspect that this may have been due to our limited sample size (VL/VL n=41; 
S/S n=38). Given that the decline in factor score (memory versus executive function) 
depended on the type of model (GEE versus LMMs) used, we suspect that statistical 
power was an issue. Second, due to missingness in the dataset, we were unable to 
control for BMI, which has been associated with poorer cognitive performance 
(Gunstad et al., 2007). However, some evidence shows that BMI is associated with 
cognitive decline via hyperglycemia (Luchsinger, 2008), so by including it in the 
models as a covariate we may have risked over-adjustment. Third, we may have 
found a more robust association had we used a more accurate measure of glucose, 
such as HbA1c measures, which reflect glucose levels over the previous three 
months. Finally, the findings of this study may not be generalizable to the general 
population, because the majority of the BIOCARD cohort is White, they are very 
highly educated, and most were considered high-risk for dementia because they had 
a first-degree relative with the disease.  
In this middle-aged, cognitively healthy cohort, we found that baseline blood 
glucose level was associated with declining executive function factor score. We 
found that this relationship was stronger amongst APOE ε4 carriers, as compared to 
non-carriers, in more robust models. This suggests that even moderate difference in 
blood glucose in middle age may impact cognitive function over time. Future 
research should work to determine how glucose impacts cognitive function in 
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younger cohorts, and larger studies should determine how this relationship is 
modified by TOMM40 genotype. Additionally, efforts to improve glucose control 
through diet and physical activity, even in non-diabetics, may be important for 







Blood glucose levels and genetic factors as predictors of age of 
onset of mild cognitive impairment (MCI) and dementia symptoms 
ABSTRACT 
 Several studies have found that type II diabetes mellitus (DM) increases the 
risk of dementia. Further, studies have found that there is a synergistic interaction 
between DM and the apolipoprotein-E (APOE) ε4 allele and DM, such that those with 
both risk factors have an even greater risk of developing dementia, compared to 
those with neither or only one risk factor. The translocase of the outer 
mitochondrial membrane (TOMM) 40 gene has also been linked to dementia risk, 
and there is evidence to suggest it may interact with DM. Here, we investigated the 
association between baseline blood glucose and age of clinical mild cognitive 
impairment (MCI) and dementia symptom onset; the association between the 
interaction of APOE and blood glucose and symptom onset; and the association 
between the interaction of glucose and TOMM40 very long/very long (VL/VL) 
genotype as a risk factor for dementia. This research was conducted using 
longitudinal data from the Biomarkers of Cognitive Decline Among Normal 
Individuals: the BIOCARD cohort (n=333), which enrolled mainly middle-aged 
participants, most of whom were considered high risk because many had a first 
degree relative with dementia. We did not find an association between baseline 
blood glucose and age of onset of clinical symptoms in a multivariable-adjusted Cox 
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proportional hazards model (Hazard Ratio (HR)=1.00; 95% Confidence Interval 
(CI)= 0.993, 1.01). Nor did we find an interaction between glucose level and 
genotype. Future studies should more closely exam the mechanistic link between 






 As the population ages, both type II diabetes mellitus (DM) and Alzheimer’s 
disease (AD) are becoming  greater public health concerns (Administration on Aging, 
2013; Alzheimer's Association, 2014; American Diabetes Association, 2014b). 
Approximately 25 percent of older adults have DM, and it is estimated that 50 
percent of older adults are pre-diabetic (American Diabetes Association, 2014b). 
Similarly, AD and mild cognitive impairment (MCI), which is commonly a prodrome 
of  AD, are both highly prevalent. Approximately 5 million older adults have been 
diagnosed with AD, and this number is expected to increase three-fold by 2050 
(Herbert, Scherr, Bienias, Bennett, & Evans, 2003). Further, it has been estimated 
that 10 to 20 percent of people over the age of 65 have MCI (Hanninen, Hallikainen, 
Tuomainen, Vanhanen, & Soininen, 2002; Lopez et al., 2003; Roberts et al., 2008), of 
whom 10 to 30 percent are estimated to progress to dementia annually (Fischer et 
al., 2007; Petersen et al., 1999).  
 Many studies, both cross-sectional and longitudinal, have found that DM is 
associated with an increased risk for MCI and AD (Cukierman et al., 2005; Irie et al., 
2008; Peila et al., 2002). Meta-analyses have estimated that DM is associated with a 
1.33 to 2.05 increased risk of AD (Lu et al., 2009; Vagelatos & Eslick, 2013). A study 
that used population attributable risk calculations found that 6 to 10 percent of 
dementia cases are directly attributable to DM (Kloppenborg et al., 2008). Further, 
studies have found that DM significantly increases the risk of MCI (G. Cheng et al., 
2012). Diabetics have extended periods of hyperglycemia and hyperinsulinemia, 
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which may play a factor in the development of AD many years before clinical 
symptoms develop (Launer, 2005; W. Xu et al., 2009). Further, diabetics who have 
had DM for longer and who have more poorly controlled glucose and insulin levels 
are at even greater risk of developing AD (Roberts, Knopman, Przybelski, et al., 
2014; Saczynski et al., 2009; West et al., 2014). 
 Two genetic factors have also been linked to an increased risk of AD. The 
apolipoprotein-E (APOE) ε4 allele has been shown to be one of the most reliable and 
strongest risk factors for risk of AD (Chartier-Harlin et al., 1994). More recently, 
translocase of the outer mitochondrial membrane (TOMM) 40 long (L) and very 
long (VL) alleles, have also been associated with increased risk of AD and earlier age 
of onset of late onset AD compared to the short (S) allelic variation (Roses, 2010; 
Roses et al., 2010). Studies have also found that there may be an interaction 
between these genetic factors and DM. Findings from a meta-analyses show that 
individuals with both an ε4 allele and DM have an even greater risk of developing 
AD, compared to individuals with just one or neither of those risk factors (Vagelatos 
& Eslick, 2013). One study found that persons with both DM and one ε4 allele have a 
5.5 times increased risk of AD (Haan et al., 1999), whereas those with DM without 
an ε4 allele have approximately twice the risk of AD (Vagelatos & Eslick, 2013), and 
those with one ε4 allele without DM have a two to three times increased risk (Farrer 
et al., 1997). To our knowledge, only one study has investigated the risk relationship 
of TOMM40 in diabetics on cognitive outcomes (Greenbaum et al., 2014). 
Pathophysiological evidence suggests a potential synergistic interaction between 
TOMM40 and diabetes on dementia. TOMM40 is involved in mitochondrial function 
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and metabolic changes, suggesting that it plays a role in both AD and DM (Caspersen 
et al., 2005; Hansson Petersen et al., 2008; Hayden et al., 2012; Hirai et al., 2001; 
Mosconi, 2005; Potkin et al., 2009).  
 This study used data from participants in the Biomarkers of Cognitive 
Decline Among Normal Individuals: the BIOCARD cohort.  We investigated the 
association between baseline glucose level and age of onset of symptoms of MCI or 
AD; the association between the interaction between baseline glucose level and 
APOE genotype and the age of onset of symptoms; and the association between the 
interaction between baseline glucose level and TOMM40 genotype and the age of 
onset of symptoms. We hypothesized that higher glucose levels would increase the 
risk of developing MCI or AD, and that higher glucose levels in combination with a 
genetic risk factor (i.e., an ε4 allele or a TOMM40 long allele) would further increase 
this risk. 
METHODS 
BIOCARD Study  
At baseline, the BIOCARD cohort (n=349) was middle-aged and high risk for 
dementia; it was designed to investigate risk factors for and the very early stages of 
cognitive impairment and dementia. The study was initially conducted at the 
National Institutes of Health (NIH) from 1995 to 2005; in 2005 the study was 
discontinued for administrative reasons. The study was re-initiated at the Johns 
Hopkins University School of Medicine in 2009 (PI: Marilyn Albert, PhD). A total of 
89 percent of the participants have been reenrolled; 38 participants are now 
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deceased. No new participants are currently being enrolled, but the BIOCARD 
research team is continuing to collect data on the original cohort and analyze data 
that were collected at the NIH (Moghekar et al., 2013; Soldan et al., 2013).  
When enrolled, participants underwent a two-day comprehensive exam at 
the Clinical Center of the NIH. They completed a clinical and neurological exam, as 
well as a neuropsychological battery, structural magnetic resonance imaging (MRI) 
scans, and standard blood work. Some participants also volunteered to have 
samples of their cerebrospinal fluid (CSF) collected via a lumbar puncture. 
Participants had annual follow-up exams. Every year participants completed clinical 
and neurological exams and a neuropsychological battery, and every other year they 
also completed MRI scans and CSF draws.  
Participants 
 By design, BIOCARD participants were generally considered high-risk for 
dementia, as approximately three-quarters of participants had a first-degree 
relative with dementia. At enrollment, most participants were middle-aged 
(mean=57.2, standard deviation (SD)=10.3). Participants were excluded from the 
study if they had cognitive impairment, or a significant medical, psychiatric, or 
neurological disorder (e.g., severe cardiovascular disease, substance abuse, or 
epilepsy). Informed consent was obtained from all participants.  
Glucose and Diabetes Measures 
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 During the clinical exam, BIOCARD participants had a routine blood draw 
from which fasting blood glucose was measured. Of the 349 participants, 333 had a 
baseline glucose level recorded (mean=99.1 mg/dL, SD=24.6). DM diagnosis was 
self-reported. At the clinical exam each participant was asked if a doctor had ever 
diagnosed them with DM. Participants were also asked about medication use, 
including diabetes medication (e.g., Metformin, injectable insulin, etc.). 
Genotyping 
 Both APOE and TOMM40 genotypes were determined from blood samples 
using restriction endonuclease digestion of polymerase chain reaction amplified 
genomic DNA; this was completed by Athena Diagnostics (Worcester, MA). APOE 
genotype was ascertained at the NIH, and TOMM40 genotype was determined after 
the study was re-initiated at Johns Hopkins University, using stored blood samples.  
Time to MCI or Dementia Symptom Onset  
 Consensus dementia diagnosis was performed annually for each participant 
at Johns Hopkins University. The BIOCARD clinical core, which consists of expert 
neurologists, neuropsychiatrists, research nurses, and research assistants, 
completed the diagnoses. This team reviewed changes in performance on the 
BIOCARD neuropsychological battery, reports from the participant and informants 
(e.g., a family member) regarding changes in cognition using the Clinical Dementia 
Rating (CDR) scale, and other potentially relevant clinical data. This information was 
used to determine if the participant was cognitively normal, or had MCI or dementia. 
If the participant was diagnosed with MCI or dementia, the team also worked to 
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determine the age of onset and cause of the impairment (e.g., AD, Parkinson’s 
disease, vascular dementia, etc.). This same method of diagnosis was applied 
posthumously to deceased participants. Currently, 63 participants have been 
diagnosed with either MCI or late-onset AD dementia (MCI n=49; AD dementia 
n=14) (Albert et al., 2013).  
Additional Variables 
 Participants also reported their age, the number of years of schooling they 
completed, and their race. Additionally, participants were asked if they had a first 
degree relative who had dementia (e.g., parent, sibling). Participants were also 
asked about their medical history, their mental health conditions, and smoking and 
substance use history. The clinical exam also included height and weight 
measurements, blood pressure measurements, heart rate, a standard blood panel 
(e.g., cholesterol, potassium, bilirubin), and a standard neurological exam.  
Statistical Analyses 
To identify differences in participant characteristics by genotype, we used 
chi-squared analyses and Student’s t-test. We used Cox proportional hazards models 
to determine the association between baseline glucose level and time to onset of 
clinical MCI and dementia symptoms, as determined by consensus diagnosis. We 
chose this time point as the failure time because of the four-year gap in the study 
between when the study was discontinued at the NIH (2005) and reinitiated at 
Johns Hopkins (2009), during which the participants were not contacted; therefore, 
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by using the estimated age of onset we were able to in essence eliminate the time 
gap from the analyses (Albert et al., 2014).  
Similarly, we used Cox regression analyses to determine the association 
between baseline glucose level and APOE or TOMM40 genotype and time to 
symptom onset by creating interaction terms between glucose and APOE and 
glucose and TOMM40. We chose to use a p-value cut-off of 0.10 or less for our 
interaction terms to determine whether to stratify the results. To examine the 
interaction between glucose and APOE, we first examined the unadjusted 
association (Model 1). In Model 2, we included sex, education, and race. Model 3 
included the same covariates as Model 2 plus medical conditions (i.e., cardiovascular 
conditions, traumatic brain injury (TBI), hypertension, hypercholesterolemia, and 
depression). These variables were coded dichotomously (i.e., ‘0’ or ‘1’), based on 
whether the participant did not or did have the medical or mental condition.   
To examine the interaction between glucose and TOMM40, we restricted the 
sample to only those participants who were APOE ε3 homozygotes. This was done 
because some studies have shown that the TOMM40 S allele is associated with poor 
cognitive outcomes in APOE ε3/4 carriers (Gold et al., 2012; Gold et al., 2010; 
Greenbaum et al., 2014; Lyall et al., 2014) and by excluding APOE ε2 and ε4 carriers 
we were able to further isolate the effect of TOMM40; ε2 and ε4 have also been 
linked to cognitive outcomes (Gold et al., 2012; Gold et al., 2010; Greenbaum et al., 
2014; Lyall et al., 2014). We also chose to only compare S allele homozygotes to VL 
allele homozygotes, because the L allele is in such high linkage disequilibrium with 
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the ε4 allele that, again, it would be difficult to determine the independent 
association of TOMM40 (Greenbaum et al., 2014). Finally, we restricted TOMM40 
analyses to Caucasians, because early research has shown that non-Caucasian 
groups have a different number of poly-T repeats at the ‘523’ locus, which is the 
length that determines allelic length (i.e., S, L, VL) associated with cognitive 
outcomes. Future research in other race and ethnic groups will provide more 
information about poly-T length and risk association in more diverse samples, but at 
this time it is more conservative to restrict analyses to Caucasians (Roses et al., 
2014). For the purposes of statistical analyses, we coded participants with an ε4 as 
‘1’ and those without were coded as ‘0.’ Similarly, we coded participants with the 
VL/VL genotype as ‘1’ and those with the S/S genotype were coded as ‘0.’ All 
analyses were completed using Stata 12.0 (StataCorp, 2009 College Station, TX). 
RESULTS 
Participant Characteristics 
Of the participants with a blood glucose measure at baseline, over half (58%) 
were female, most (98%) were White, they had a mean age of 56.9 years (SD=10.2), 
and a high mean level of education (mean=17.1 years, SD=2.4). Participants were 
also generally healthy; the mean body mass index (BMI) was 26.4 kg/m2 (SD=5.8), 
and there was a relatively low prevalence of medical conditions (i.e., cardiovascular 
disease, hypertension, hypercholesterolemia, traumatic brain injury (TBI)) (Table 1). 
Of the 333 participants with complete glucose data, 109 (32.7%) were ε4 carriers. 
Those with one or more ε4 alleles were more likely to have hypercholesterolemia 
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and depression, compared to those without an ε4 allele. Of the White participants 
with complete glucose data and the APOE ε3/ε3 genotype, 55 had the TOMM40 
VL/VL genotype and 56 had the S/S genotype. There were no differences in 
participant characteristics between those with the VL/VL genotype and those with 
the S/S genotype (Table 1). 
Effect of baseline glucose level on symptom onset 
 There was no association between baseline glucose level and age of clinical 
symptom onset in an unadjusted model (Hazard Ratio (HR)= 1.00, 95% confidence 
interval (CI)=0.996, 1.01). Nor was glucose associated with symptom onset after 
adjustment for years of education, sex, and race (HR=1.00; 95% CI 0.996, 1.01). The 
association remained non-significant when we added medical conditions as 
covariates (HR=1.00; 95% CI 0.993, 1.03) (Table 8). The association between 
glucose and age of symptom onset did not vary by APOE (for all 3 models, 
interaction term p-values>0.10) or TOMM40 (for all 3 models, interaction term p-
values>0.10) genotype.  
DISCUSSION 
This study examined the association between baseline glucose level and 
onset of clinical symptoms of MCI or dementia in the BIOCARD cohort. Further, we 
investigated the association between the interaction between glucose and APOE and 
glucose and TOMM40 and clinical symptom onset. We found no association between 
glucose levels and clinical symptom onset and no association between interactions 
between glucose and genotype, either APOE or TOMM40, and age of symptom onset. 
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Several studies have found that higher levels of glucose, insulin resistance, 
and DM are all associated with risk of MCI and dementia (Vagelatos & Eslick, 2013). 
It has also been established that the ε4 allele is one of the strongest risk factors for 
MCI and dementia (Chartier-Harlin et al., 1994). Further, studies have found a 
positive interaction between DM and the ε4 allele with respect to cognitive 
outcomes, suggesting that those with the ε4 risk allele are at greater risk of 
developing MCI or dementia if they also have higher blood glucose levels, insulin 
resistance, or confirmed DM, compared to those with either the risk allele or DM (S. 
T. Cheng et al., 2012; Vagelatos & Eslick, 2013). Finally, new evidence suggests that 
the VL TOMM40 allele is associated with earlier age of onset of late onset AD (Roses, 
2010; Roses et al., 2010).  To our knowledge, this is the first study examining the 
association between the interaction of glucose level and TOMM40 and onset of 
clinical MCI and dementia symptoms; however, past studies in samples of diabetics 
have shown that those with the VL/VL genotype have worse cognitive performance 
than those with the S/S genotype (Greenbaum et al., 2014). 
This study has many strengths, including its longitudinal design and unique 
cohort; however, the study also has some limitations. The BIOCARD study enrolled 
middle-aged, healthy subjects, so relatively few participants developed MCI or 
dementia at the time of analysis. Therefore, there may be limited power for 
detecting an association between baseline glucose and clinical symptom onset. We 
may be able to observe an association between glucose and onset of clinical 
symptoms when more participants develop MCI or dementia. Additionally, although 
blood glucose was measured in this study, more reliable measures of DM, such as 
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HbA1c, were not collected. These limitations may have attenuated the observed 
effect that glucose, and by extension DM, had on age of onset of clinical symptoms. 
We were not able to control for BMI in this study, as few participants had complete 
baseline height and weight data. Evidence has shown that BMI may be associated 
with risk of dementia (Tolppanen et al., 2014); conversely, it may be that BMI is 
associated with increased risk of dementia through hyperglycemia, so if we had 
controlled for BMI it would have been over-adjustment (Luchsinger, 2008). Finally, 
the findings of this study may not be generalizable to the general population, 
because participants had a high mean level of education and most were Caucasian.  
Future studies are needed to further examine the link between DM and 
dementia and mechanisms that may connect the two conditions. Further, although 
the relationship between DM and risk of dementia by APOE genotype has been well 
defined (Vagelatos & Eslick, 2013). Further studies are needed in order to 
determine whether and how the association between DM and risk of dementia is 
modified by TOMM40 genotype. It has been suggested that as much as a quarter of 
dementia cases—the majority of which are due to AD—might be avoided by 
addressing modifiable risk factors, such as DM (Barnes & Yaffe, 2011). DM may be of 
particular importance because it is so prevalent amongst older adults, but it also a 
treatable and preventable disease (American Diabetes Association, 2014b). Given 
that there is no current effective treatment for AD, research that better defines the 
risk and mechanisms between modifiable risk factors and dementia will play an 




Blood glucose levels and genetic factors as predictors of cortical 
thinning 
ABSTRACT 
Currently, there is no cure for Alzheimer’s disease (AD), so identifying biomarkers 
to diagnose and intervene in the preclinical stages may be the most effective way to 
alter the course of AD. Cortical thinning in the entorhinal cortex, inferior temporal 
gyrus, parahippocampal gyrus pars triangularis, precuneus, superior frontal and 
parietal gyri, supramarginal gyrus, and temporal pole is thought to occur early in AD, 
thus representing a non-invasive marker for predicting progression to AD. It is also 
thought that modifiable risk factors for dementia, including type II diabetes mellitus 
(DM), may represent an important target for reducing the prevalence of AD. 
Additionally, genetic markers, including the apolipoprotein E (APOE) ε4 allele and 
the translocase of the outer mitochondrial membrane (TOMM) 40 very long (VL) 
allele, may modify this relationship. Here, we investigated the cross-sectional 
association between baseline blood glucose level and cortical thinning in a sample of 
middle-aged, cognitively normal adults. We also investigated the interaction 
between glucose and APOE and glucose and TOMM40, to determine whether 
genotype affected this relationship. At baseline, 333 participants in the Biomarkers 
of Cognitive Decline Among Normal Individuals: the BIOCARD cohort had a baseline 
fasting glucose measure, and a subset (n=269) had cortical thickness measures in 
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AD signature regions as measured by magnetic resonance imaging (MRI) scans. In a 
model adjusted for age, sex, race, education, and medical conditions, higher blood 
glucose was associated with a thinner parahippocampal gyrus (B=-0.002; 95% CI -
0.003, -0.0001) and temporal pole (B=-0.002; 95% CI -0.003, -0.0002). When we 
examined the association between glucose and cortical thickness in a model that 
controlled for sex and age alone, we found that ε4 carriers versus non-carriers had 
thinner superior parietal gyri (B=-0.001; 95% CI -0.002, 0.0005 vs. B=0.0007; 95% 
CI 3.05e-6, 0.001) and temporal pole (B=-0.004; 95% CI -0.008, -0.0009 vs. B=-
0.0003; 95% CI -0.002, 0.001) measures. These findings suggest that higher blood 
glucose levels may be associated with the presence of gray matter atrophy 
consistent with that observed in AD as early as middle age. Future studies should 





 Alzheimer’s disease (AD) is a growing problem in the United States. Over five 
million older adults have AD, and this number is expected to triple by 2050 (Herbert 
et al., 2003). Currently, there is no cure for AD, so it may be that intervening during 
the prodromal or preclinical stages is the most effective course for slowing cognitive 
decline associated with AD (Barnes & Yaffe, 2011; Deschaintre, Richard, Leys, & 
Pasquier, 2009). Many types of biomarkers, including blood biomarkers, 
cerebrospinal fluid (CSF) biomarkers, and imaging markers, are being explored with 
the hopes of diagnosing AD earlier in the disease course, and altering the trajectory 
of the decline (Lewczuk, Mroczko, Fagan, & Kornhuber, 2014; Mielke & Haughey, 
2012). Cortical thickness, which is a measure of gray matter atrophy, can be 
measured by magnetic resonance imaging (MRI) scans, is one marker that may be 
prognostic of AD (Desikan et al., 2009; Dickerson et al., 2009). 
 Past studies have found that cortical thinning occurs in the prodromal stages 
of AD (Desikan et al., 2009; Desikan et al., 2008; Dickerson et al., 2009). There have 
been few studies that have investigated cortical thinning in the preclinical stages of 
AD. However, it has been found that in preclinical patients, cortical thinning in the 
entorhinal cortex, inferior temporal gyrus, parahippocampal gyrus pars triangularis, 
precuneus, superior frontal and parietal gyri, supramarginal gyrus, and temporal 
pole is observed in those with substantial amyloid burden (Dickerson et al., 2009), 
and that this thinning is associated with greater risk of cognitive decline and 
transition to dementia (Dickerson et al., 2011; Dickerson & Wolk, 2012). 
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Additionally, findings from the BIOCARD study have shown that lower average 
cortical thickness at baseline was associated with an increased risk of developing 
AD, and cortical thinning in AD-specific regions is associated with earlier onset of 
AD (Pettigrew et al., 2014). 
 Some modifiable risk factors for AD have also been implicated as risk factors 
for cortical thinning.  Type II diabetes mellitus (DM) is one such factor.  An 
estimated one-third of older adults have DM, and one-half are pre-diabetic 
(American Diabetes Association, 2014b). DM is associated with an increased risk of 
AD; diabetics have been shown to have 33% to 200% increased risk of developing 
AD, compared to non-diabetics (Vagelatos & Eslick, 2013). Further, studies in 
cognitively normal participants have shown that diabetics have reduced mean 
cortical thickness has compared to non-diabetics (Brundel, van den Heuvel, de 
Bresser, Kappelle, & Biessels, 2010). Cross-sectional analyses have shown that 
higher glucose and HbA1c levels are associated with grey matter atrophy in the left 
anterior cingulate region and the bilateral occipital regions (Z. Chen et al., 2015; 
Leritz et al., 2011). Another cross-sectional study in a middle-aged, cognitively 
normal cohort showed the diabetics had greater cortical thinning globally, and in 
the frontal and parietal lobes (van Velsen et al., 2013). 
 Two genes have also been linked with risk of AD, and may modify the 
relationship between DM and cognitive decline, risk of dementia, and brain atrophy. 
The first gene, APOE, is an established risk factor for late onset AD (LOAD). The ε4 
allele, as compared to the ε2 or ε3 alleles, is associated with increased risk of AD 
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(Farrer et al., 1997), cognitive decline (Caselli et al., 2007; Caselli et al., 2004), and 
smaller brain volumes and cortical thinning (Espeseth et al., 2008; Fennema-
Notestine et al., 2011). More recently, TOMM40, which has three allelic variations – 
short (S), long (L), and very long (VL), – has also been linked to LOAD. Compared to 
the TOMM40 short (S) allele, the very long (VL) allele is associated with earlier 
onset of LOAD (Roses et al., 2010), smaller brain volumes, and poorer cognitive 
performance (Ferencz et al., 2013).  Further, there is evidence to suggest an 
interaction between DM and APOE and DM and TOMM40 that compounds the risk 
for poor cognitive outcomes (Greenbaum et al., 2014; Hayden et al., 2012; Potkin et 
al., 2009; Vagelatos & Eslick, 2013).  
We determined the cross-sectional association between baseline glucose and 
cortical thickness in the Biomarkers of Cognitive Decline Among Normal 
Individuals: the BIOCARD cohort, a middle-aged, healthy, cognitively normal sample.  
We also examined how APOE and TOMM40 modify the relationship between 
glucose and cortical thickness.  We hypothesized that higher baseline blood glucose 
would be associated with greater grey matter atrophy, and that this relationship 
would be stronger among those with the APOE and TOMM40 risk alleles.  
METHODS 
BIOCARD Study  
The BIOCARD (n=349) Study started at the National Institutes of Health 
(NIH) in 1995. The study was designed in order to investigate risk factors for 
cognitive decline and dementia in a healthy, mainly middle-aged, high-risk cohort. 
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The study was discontinued in 2005, and re-initiated in 2009 at the Johns Hopkins 
University School of Medicine (PI: Marilyn Albert, PhD). Currently, 89% of the 
participants have been reenrolled, and 38 participants have died (Moghekar et al., 
2013; Soldan et al., 2013).  
At baseline, participants completed a two-day exam at the Clinical Center of 
the NIH where they completed a clinical and neurological exam, cognitive testing, 
MRI, and standard blood assays. A subset of participants also completed a lumbar 
puncture in order to draw samples of CSF. At annual follow-up exams, participants 
completed physical and neurological exams and cognitive testing; every two years 
they also completed MRI scans and CSF collection while the study was being 
conducted at the NIH.  
Participants 
 At baseline, most participants were middle-aged (mean=57.2, standard 
deviation (SD)=10.3). The cohort was also considered high-risk for developing 
dementia, because approximately three-quarters of participants had a first-degree 
relative with dementia. Exclusion criteria included cognitive impairment, and 
significant medical, psychiatric, or neurological disorder (e.g., severe cardiovascular 
disease, Parkinson’s disease, or epilepsy). The current study used data from 333 of 
the participants who had complete data for fasting blood glucose at baseline. 
Informed consent was obtained from all participants.   
Glucose and Diabetes Measures 
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 Fasting blood glucose was obtained from standard blood draws completed at 
baseline and follow-up visits. A total of 333 participants had complete data for 
baseline blood glucose level (mean=99.1 mg/dL, SD=24.4). DM status was 
ascertained during the clinical exam, when participants were also asked to report 
medication use, including DM medication (e.g., Metformin, injectable insulin, etc.). 
Genotyping 
 APOE genotyping was completed at the NIH. TOMM40 genotyping was 
completed using stored blood samples after the study had been reinitiated at Johns 
Hopkins. Genotyping was completed at Athena Diagnostics (Worcester, MA), using 
restriction endonuclease digestion of polymerase chain reaction amplified genomic 
DNA. In our analyses, we coded participants with one or more ε4 alleles as ‘1’ and 
those without an ε4 allele as ‘0.’ In the TOMM40 analyses, those with the VL/VL 
genotype were coded as ‘1,’ while those with the S/S genotype were coded as ‘0.’ 
Cortical Thickness Measures 
While the study was being conducted at the NIH (1995-2005), MRI scans 
were completed every other year. At baseline, 335 participants completed an MRI 
scan. Scans were completed on a 1.5 Tesla General Electric scanner. The scanning 
protocol involved localizer scans, axial Fast Spin Echo sequence (TR = 4250, TE = 
108, FOV = 512 × 512, thickness/gap = 5.0/0.0 mm, flip angle = 90, 28 slices), Axial 
Flair sequence (TR = 9002, TE = 157.5, FOV = 256 × 256, thickness/gap = 5.0/0.0 
mm, flip angle = 90, 28 slices), Coronal Spoiled Gradient Echo sequence (TR=24, TE- 
2 FOV = 256 × 256, thickness/gap = 2.0/0.0 mm, flip angle = 20, 124 slices), and 
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Sagittal Spoiled Gradient Echo sequence (TR = 24, TE = 3, FOV = 256 × 256, 
thickness/gap = 1.5/0.0 mm, flip angle = 45, 124 slices) (Miller et al., 2013). Cortical 
thickness measures were obtained from MRI scans using FreeSurfer Version 5.0 for 
269 participants at baseline. This study examined AD-signature regions, which were 
based on findings from the research conducted by Dickerson and colleagues (2009; 
2011). Thickness of AD-signature regions considered both spatial intensity 
gradients and signal intensity of the scans, and were determined by estimating the 
space from the boundary of grey matter and white matter to the boundary between 
grey matter and CSF (Fischl & Dale, 2000). These methods have shown good validity 
and reliability (Han et al., 2006; Kuperberg et al., 2003; Rosas et al., 2002; Salat et al., 
2004).  
Additional Variables 
 During the clinical exams, a standard demographic profile and medical 
history were recorded, including age, number of years of education, race, family 
history of dementia, and current or past medical conditions (e.g., cardiovascular 
disease, metabolic conditions, and smoking and substance abuse). Participants’ 
height and weight were also measured, and these measures were used to calculate 
body mass index (BMI; kg/m2). Additionally, blood pressure measurements, heart 
rate, a standard blood panel (e.g., glucose, potassium, bilirubin), and a standard 




We used chi-squared tests and Student’s t-tests to compare participant 
demographic variables by genotype (i.e., ε4-carrier versus non-carrier and S/S 
versus VL/VL). We used linear regression models to determine the association 
between baseline blood glucose level and cortical thickness. In Model 1, we 
controlled for age, years of education, and sex. In Model 2, we controlled for age, 
education, sex, and baseline medical conditions (i.e., cardiovascular disease, 
hypertension, hypercholesterolemia, traumatic brain injury, and depression). To 
examine the interaction between glucose and APOE and the interaction between 
glucose and TOMM40, we created two interaction terms. We conducted these 
analyses including these interaction terms, and if the interaction coefficient was 
significant at a level of p<=0.10, we stratified the analyses to determine the 
difference in association between the genotypes.  
To examine the interaction between glucose and TOMM40, we restricted the 
sample to only those participants who were APOE ε3 homozygous. This is because 
evidence has suggested that the S allele is associated with poorer cognitive 
outcomes in ε3 heterozygotes (Gold et al., 2012; Gold et al., 2010; Greenbaum et al., 
2014; Lyall et al., 2014). This restriction also helped to nullify any effect that the ε2 
and ε4 alleles might have on cortical thickness (Gold et al., 2012; Gold et al., 2010; 
Greenbaum et al., 2014; Lyall et al., 2014). Additionally, because the L allele is in 
high linkage disequilibrium with the ε4 allele, we compared people with the VL/VL 
genotype to people with the S/S genotype (Greenbaum et al., 2014). TOMM40 
analyses also did not include any non-White participants, because early evidence 
has suggested that, like APOE, TOMM40 alleles and associated risk vary by race and 
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ethnic group. However, these variations are not yet well understood, so we chose to 
take the conservative approach of limiting the sample (Roses et al., 2014). 
Additionally, some participants were excluded from analyses because the 
FreeSurfer measures were not reliable. All analyses were completed using Stata 12.0 
(StataCorp, 2009). 
RESULTS 
Participant Characteristics   
 Over half (58%) of participants were female, and participants were generally 
middle-aged at baseline (mean=56.9, SD=10.2). The majority of participants were 
White (98%), and they had a high mean level of education (17.1 years, SD=2.4). The 
average body mass index (BMI) was 26.4 kg/m2 (SD=5.8), and the sample was 
relatively healthy, with low prevalence of medical conditions (i.e., cardiovascular 
disease, hypertension, hypercholesterolemia, or traumatic brain injury) (Table 1). 
There were 109 participants with one or more APOE ε4 alleles, and 222 without an 
ε4 allele. Those with an ε4 allele were more likely to have history of 
hypercholesterolemia and depression, as compared to non-carriers. Of the White 
participants who were APOE ε3 homozygous, 55 had the TOMM40 VL/VL genotype 
and 56 had the S/S genotype. There were no other significant differences by 
genotype. At baseline, the average fasting blood glucose level was 99.1 mg/dL 
(SD=24.6). 
Blood Glucose and Cortical Thickness 
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 In a model that controlled for age and sex, higher fasting blood glucose levels 
were associated with lower cortical thickness in the pars triangularis of the inferior 
frontal gyrus (B=-0.0007; 95% CI -0.001, -0.0001) (Table 9). In Model 2, which 
controlled for age, education, race, sex, and medical conditions, glucose was 
associated with thinner parahippocampal gyrus (B=-0.002; 95% CI -0.003, -0.0001) 
and temporal pole (B=-0.002; 95% CI -0.003, -0.0002) measures. In Model 1, we 
found that the association between glucose and grey matter atrophy was stronger 
among those with an APOE ε4 allele. Among those without an e4 allele, higher 
glucose levels were associated with thicker superior partietal gyri (B=0.0007 95% 
CI 3.05e-6, 0.001), compared to those with an e4 allele (B=-0.001; 95% CI -0.002, 
0.0005; interaction term p=0.035). Further, higher glucose levels were associated 
with significantly thinner temporal pole measures in e4 carriers (B=-0.004; 95% CI -
0.008, -0.0009) versus non-carriers (B=-0.0003; 95% CI-0.002, 0.001; interaction 
term p=0.049) (Table 10). This association was no longer significant after 
stratification in fully adjusted models (interaction term p=0.041). There was no 
interaction between glucose and TOMM40 genotype (all interaction term p-
values>0.10). 
DISCUSSION 
 This study investigated the cross-sectional association between blood 
glucose level and cortical thickness, and how this association is affected by APOE 
and TOMM40 genotype, in a health, cognitively normal, middle-aged sample. We 
found that higher baseline glucose was significantly associated with decreased 
 78 
 
cortical thickness in three AD signature regions, including the parahippocampal 
gyrus, pars triangularis, and temporal pole. Additionally, we found that higher 
glucose levels were associated with thinner superior parietal gyrus and temporal 
pole measures in subjects with one or more ε4 alleles, as compared to those without 
an ε4 allele. The parahippocampal gyrus, which surrounds the hippocampus and is 
important for memory encoding and retrieval, is affected early in AD (Dickerson et 
al., 2009; Dickerson et al., 2011). Similarly, the pars triangularis, which partially 
makes up Broca’s area and is associated with semantic tasks, has been implicated as 
a region of interest that might be affected early in the course of AD (Dickerson et al., 
2009; Dickerson et al., 2011). The temporal pole is involved in executive functioning 
tasks, such as theory of mind, which allows an individual to understand another 
individual’s perspective (Olson, Plotzker, & Ezzyat, 2007), and the superior parietal 
gyrus is involved in attention shifting (Vandenberghe, Gitelman, Parrish, & Mesulam, 
2001). 
 Previous studies have found that among AD patients, those with 
cardiovascular conditions, including DM, have greater grey matter atrophy in the 
hippocampus (Donix et al., 2013), suggesting that treatment of cardiovascular 
conditions might slow the cognitive decline in AD patients, and possibly in the 
prodromal and preclinical stages of AD (Deschaintre et al., 2009). In fact, studies 
have found that among diabetics with cortical thinning, one year of insulin therapy 
results in increases in cortical thickness (Z. Chen et al., 2015). The findings from our 
study suggest that even before any clinical symptoms of AD manifest, glucose may 
have a measureable negative effect on brain integrity. Early identification of 
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biomarkers, such as cortical thickness, related to AD may present an opportunity to 
significantly alter the course of the disease. Evidence shows that intervening after 
AD symptoms present is not effective; additionally, treatment efforts for AD have 
failed to this point (Lambracht-Washington & Rosenberg, 2013). However, 
intervening on modifiable risk factors (e.g., DM) in middle age or later middle age 
may significantly reduce the risk of or delay the onset of AD (Barnes & Yaffe, 2011). 
Identifying individuals at greatest risk for or in the earliest stages of AD via 
biomarkers, like grey matter atrophy, may help clinicians to better focus these 
intervention efforts. 
 This study has multiple limitations. First, we used blood glucose levels, as 
opposed to more accurate HbA1c measures, which are a measure of glucose over a 
period of three months. However, it is noteworthy that we found an association 
between glucose and cortical thickness, because this suggests that even modest 
fluctuations in glucose may affect cortical thickness. Second, we did not observe 
interaction between glucose and TOMM40. This may have been because of the 
relatively small sample size used when comparing VL homozygotes (n=55) to S 
homozygotes (n=58). Future research should work to elucidate any interaction 
between glucose and TOMM40 in larger samples, and investigate how other 
TOMM40 genotypes affect the relationship between glucose or DM and cortical 
thickness. Third, many participants were missing BMI data at baseline, so we were 
not able to include it as a covariate in the models. BMI has been linked with brain 
atrophy (Gunstad et al., 2008), but this association may be through hyperglycemia 
(Luchsinger, 2008). Therefore, had we included BMI as a covariate, we would have 
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risked over-adjustment. Fourth, this study sample was primarily White and had a 
high mean level of education, and most participants had a first-degree relative with 
dementia, making it a high-risk cohort. These characteristics may mean that the 
findings are not generalizable to the population as a whole. Finally, because this 
study was cross-sectional, we cannot infer causality from our findings. 
 Our results suggest glucose levels may promote cortical thinning, which may 
be a useful biomarker for identifying individuals in the preclinical stages of AD. 
Without a cure for AD, treatment for modifiable risk factors, such as DM, may be the 
most effective way to slow or, even halt, the progression of AD. Moving forward, it 
will be important to better understand how early cortical thinning predicts AD onset, 






This research investigated the association between baseline blood glucose and 
cognitive test performance over time, time to MCI or AD symptom onset, and grey 
matter atrophy in AD-signature regions. Results indicate that even modest increases 
in blood glucose in mid-life are associated with reduced cortical thickness in AD-
signature regions and decline in executive function. These findings suggest that 
controlling blood glucose levels even in non-diabetics may be important for 
maintaining brain health and cognitive function with advancing age. 
 There is substantial evidence showing that hyperglycemia is associated with 
poorer cognitive function. Impaired glucose tolerance has been widely associated 
with poorer verbal, logical, working, and visuospatial memory (Lamport et al., 2009). 
Studies have also shown that acute hyperglycemia in type II diabetics is associated 
with poorer performance on tasks involving information processing, working 
memory, and attention (Sommerfield, Deary, & Frier, 2004). Hyperglycemia may 
result in cognitive decline through oxidative stress, cerebral blood flow changes, and 
neural toxicity (Biessels et al., 2014; West et al., 2014). In the same line as these 
previous studies, this study found an association between baseline glucose and 
declining executive function factor score. Additionally, this study found that this 
association was stronger amongst subjects with one or more ε4 alleles, compared to 
those with none. This is consistent with findings from previous studies (Ravona-
Springer et al., 2014), and mechanistic evidence suggesting that the APOE ε4 allele is 
associated with increased neuronal stress (e.g., hyperexcitability, neuronal DNA 
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damage) and inflammation (Aboud et al., 2012; Liu et al., 2013; Lynch et al., 2003). 
Findings from this research were opposite from the expected direction in the 
analyses that examined the association between then interaction of glucose and 
TOMM40 and cognitive performance. We found that higher glucose levels predicted 
decline on executive function factor score in those with the S/S genotype, but not in 
those with the VL/VL genotype; however this may have been due to issues with 
statistical power. Mechanistic evidence suggests that the TOMM40 VL/VL allele may 
modify the association between glucose and cognitive decline via its role in 
mitochondrial function (Hayden et al., 2012; Mosconi, 2005; Potkin et al., 2009). The 
findings from this study are important, because few studies have examined the 
association between glucose and cognitive decline in younger, highly educated 
cohorts; this evidence suggests that hyperglycemia may negatively impact cognition 
regardless of cognitive reserve, and may do so more strongly among e4 carriers.  
 Although this study did not find an association between blood glucose and 
dementia or MCI symptom onset, this may have been because the BIOCARD cohort 
is still relatively young, and few (n=63) have been diagnosed with dementia or MCI 
at this point in time. In the future, an association between glucose and symptom 
onset may be detectable in this sample, which would be consistent with findings 
from earlier studies. Higher glucose levels have been associated with risk of 
dementia (Ronnemaa et al., 2009), though not consistently (Schrijvers et al., 2010). 
Studies have also shown that insulin resistance is associated with risk of dementia 
(Schrijvers et al., 2010). While some studies have shown an interaction effect with 
APOE (Haan et al., 1999; Peila et al., 2002), others have not (Schrijvers et al., 2010). 
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Based on the currently available literature, there is no evidence indicating whether a 
similar interaction effect is observed with TOMM40.   
The cross-sectional finding that blood glucose levels are associated with 
thinner parahippocampal gyrus and temporal pole measures suggests that 
hyperglycemia may impact brain tissue integrity as early as middle age. Additionally, 
findings from this study showed that higher glucose levels were associated with 
greater grey matter atrophy of the superior parietal gyrus and temporal pole among 
APOE ε4 carriers, compared to non-carriers, which may indicate that individuals 
with an ε4 allele are more susceptible to the negative effects of hyperglycemia. 
Dickerson and colleagues (2009; 2011) found that cortical thinning occurs in AD-
signature regions in the prodromal stages of AD. Studies in preclinical populations, 
including the BIOCARD cohort, have found that cortical thinning in AD-signature 
regions predicts risk of dementia and MCI symptom onset and earlier age of onset 
(Pettigrew et al., 2014). Studies in somewhat younger samples have shown that DM 
is associated with cortical thinning independent of macrovascular conditions 
(Brundel et al., 2010; Z. Chen, Li, Sun, & Ma, 2012; van Velsen et al., 2013), and that 
insulin therapy induces cortical thickening (Z. Chen et al., 2015). Studies have also 
found that hyperinsulinemia, independent of DM, is associated with cortical 
thinning in the frontal, temporal, and parietal lobes in a cognitively normal cohort 
(Yoon et al., 2014). This evidence suggests that DM is associated with substantial 
grey matter atrophy, but that better glucose control may prevent or reverse these 
effects. Additionally, while past studies have found that the APOE ε4 allele is 
associated with hippocampal volume loss (Mueller, Schuff, Raptentsetsang, Elman, & 
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Weiner, 2008), they have not found an interaction between APOE allelic variation 
and the association between DM and cortical thinning (Donix et al., 2013). This is 
the first study, to our knowledge, that has found an association between glucose 
levels and cortical thinning in a healthy, cognitively unimpaired cohort, and has 
shown that the ε4 allele may modify this relationship. 
Limitations 
Although this study had several strengths, including the unique cohort (e.g., 
middle aged at baseline, high risk for dementia due to family history), its 
longitudinal design, and wealth of measures (e.g., genotyping, multiple cognitive 
tests), the findings must be viewed alongside the limitations of the study. First, 
glucose was used as the main predictor. However, HbA1C is a more stable measure 
of blood glucose, and it may have been possible to better detect patterns of cognitive 
decline, risk of dementia, and grey matter atrophy if HbA1C measures had been 
used as the main predictor (Leritz et al., 2011; Marder et al., 2014). Second, there 
was a large amount of missingness of body mass index (BMI) data, so it was not 
possible to control for BMI as a potential confounder. BMI has been linked to brain 
shrinkage (Gunstad et al., 2008), cognitive decline (Gunstad et al., 2007), and risk of 
dementia (Tolppanen et al., 2014). However, other studies suggest that it is likely 
that BMI is actually associated with dementia and cognitive performance outcomes 
through hyperglycemia and insulin resistance (Luchsinger, 2008). Therefore, in this 
scenario, hyperglycemia would be a mediator and adjustment for BMI would be 
over-adjustment. Third, this study may have lacked significant power to detect an 
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interaction between glucose and TOMM40. The TOMM40 analyses were restricted 
to subjects who were APOE ε3 homozygotes and White, and only compared the 
VL/VL genotype to the S/S genotype, in order to be as conservative as possible; 
however, this substantially limited the sample size. Studies in larger samples may be 
able to detect an association between the interaction of glucose and TOMM40 and 
cognitive decline, risk of dementia, and brain atrophy. Finally, because the BIOCARD 
cohort is predominantly White, highly educated, and high-risk for dementia, the 
findings from this study may not be generalizable to the general population.  
Future Directions 
 The findings from this study indicate that more research should be done to 
better understand the association between glucose levels and risk of dementia and 
associated cognitive decline in preclinical AD samples. Future studies should 
investigate a more detailed history of glucose or HbA1c in non-diabetic subjects, in 
order to better understand how fluctuations in glucose levels impact risk of 
dementia, cognitive decline, and cortical thinning. The cross-sectional findings from 
this study that show glucose is associated with cortical thinning indicate that 
hyperglycemia may be an important risk factor for grey matter atrophy. However, 
longitudinal evidence is needed to confirm this association. Fortunately, as more 
data become available, it will be possible to investigate these associations in the 
BIOCARD study. It will also be important for larger studies to investigate a potential 
glucose-TOMM40 interaction. The emerging evidence that shows APOE is not the 
only gene that impacts risk of dementia (G. Li et al., 2013) is intriguing; however, 
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because genotype is not modifiable, it is important to understand how modifiable 
risk factors (e.g., DM), impact the relationship between genotype and risk of 
dementia, and the associated cognitive decline and cortical thinning. Finally, 
clinicians should be made aware that higher levels of glucose, even without a pre-
diabetes or DM diagnosis, may be putting their patients at risk for cognitive decline 
and dementia. Maintaining normal glucose levels through diet and physical activity 
may prove to be an important step for delaying the onset of or preventing cognitive 
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Table 1. Participant characteristics at baseline, n (%) or mean ± standard deviation 
 Total 
(n=333) 









Age, mean (SD) 56.9 ± 10.2 57.9 ± 7.9 56.4 ± 11.1 0.24 56.6 ± 11.8 57.1 ± 11.9 0.80 
Sex, % female 192 (58) 67 (61) 125 (56) 0.57 32 (59) 31 (54) 0.68 
Race, % Caucasian 327 (98) 105 (96) 222 (99) 0.18 N/A N/A N/A 
Education, mean (SD) 17.1 ± 2.4 17.4 ± 2.2 16.9 ± 2.4 0.12 16.7 ± 2.4 17.1 ± 2.3 0.40 
Baseline glucose (mg/dL), mean (SD) 99.1 ± 24.6 97.7 ± 25.2 99.9 ± 24.8 0.46 98.3 ± 29.5 101.9 ± 27.2 0.50 
Diabetes, % 6 (2) 0 (0) 6 (3) 0.09 1 (2) 2 (4) 0.62 
Cardiovascular conditions, % 14 (5) 6 (7) 8 (4) 0.57 5 (12) 1 (2) 0.07 
Hypertension 37 (13) 13 (14) 24 (13) 0.60 4 (9) 6 (13) 0.63 
Hypercholesterolemia  46 (17) 23 (26) 23 (12) 0.003 7 (16) 6 (13) 0.61 
TBI 11 (4) 4 (4) 7 (4) 0.84 4 (9) 1 (2) 0.12 
Depression, ever 53 (19) 25 (28) 28 (15) 0.02 9 (21) 6 (13) 0.28 
Depression, within 2 yrs of baseline 38 (14) 19 (22) 19 (10) 0.01 9 (21) 4 (9) 0.09 







Table 2. Executive function factor structure matrix: 
Correlations between variables and promax rotated 
common factors 
Variable Factor Loading 
Digit Span Back 0.4168 
DSST 0.6338 
Verbal Fluency “A” 0.4280 
WAIS Block Design 0.6506 
 
Table 3. Memory factor structure matrix: Correlations 
between variables and promax rotated common factors 
Variable Factor Loading 
Logical Memory, immediate 0.8769 
Logical Memory, delay 0.8789 
Pair Association, learning 0.4964 






Table 4. LMM: Association between baseline glucose (mg/dL) and change in factor score 
 Model 1 Model 2 
 B (95% CI) p B (95% CI) p 
Executive Function -0.004 (-0.007, -0.0005) 0.022 -0.004 (-0.008, -0.001) 0.010 
Memory 0.0005 (-0.003, 0.004) 0.805 0.0009 (-0.003, 0.005) 0.665 
Model 1 controlled for sex and age. Executive Function, n=307; Memory, n=323. Model 2 
controlled for sex, age, education, race, depression, and medical conditions. Executive Function, 
n=282; Memory, n=298. 
 
Table 5. GLM Model 1: Association between baseline glucose (mg/dL) and change in 
factor score by TOMM40 status 
 VL/VL (n=41) S/S (n=38) 
 B (95% CI) p B (95% CI) p 
Executive Function 0.004 (-0.003, 0.010) 0.283 -0.013 (-0.024, -0.002) 0.021 
Model controlled for sex and age. Interaction term, p=0.009 
 
Table 6. GEE Model: Association between baseline glucose (mg/dL) and change in factor 
score 
 Model 1 Model 2 
 B (95% CI) p B (95% CI) p 
Executive Function -0.007 (-0.010, -0.004) <0.001 -0.004 (-0.008, -0.001) 0.009 
Memory 0.0001 (-0.003, 0.003) 0.942 -0.0002 (-0.004, 0.004) 0.923 
Model 1 controlled for sex and age. Executive Function, n=307; Memory, n=323. Model 2 
controlled for sex, age, education, race, depression, and medical conditions. Executive Function, 
n=282; Memory, n=298. 
 
 
Table 7. GEE Model 2: Association between baseline glucose (mg/dL) and change in 
factor score by APOE status 
 APOE ε4 Positive (n=93) APOE ε4 Negative (n=189) 
 B (95% CI) p B (95% CI) p 
Executive function -0.013 (-0.020, -0.006) <0.001 -0.005 (-0.009, -0.002) 0.002 

















Table 8. Cox regression: Association between baseline glucose (mg/dL) and time to 
symptom onset 
 Hazard Ratio (95% CI) p 
Model 1 1.00 (0.996, 1.01) 0.655 
Model 2 1.00 (0.996, 1.01) 0.653 
Model 3 1.00 (0.993, 1.01) 0.928 
Model 1 is unadjusted. Model 2 is adjusted for years of education, sex, and race. Model 3 is adjusted for the 






Table 9. Linear regression: Cross-sectional association between baseline glucose (mg/dL) and 
cortical thickness at baseline 
 Model 1 Model 2 
 B (95% CI) p B (95 % CI) p 
Entorhinal cortex -0.0006 (-0.002, 0.002) 0.943 -0.001 (-0.003, 0.0005) 0.171 
Inferior temporal gyrus -0.0006 (-0.0007, 0.0006) 0.846 0.0002 (-0.0005, 0.0009) 0.577 
Parahippocampal gyrus -0.001 (-0.002, 0.0003) 0.119 -0.002 (-0.003, -0.0001) 0.036 
Pars triangularis -0.0007 (-0.001, -0.00001) 0.045 -0.0007 (-0.001, 0.0001) 0.092 
Precuneus -0.00009 (-0.0007, 0.0005) 0.776 -0.0001 (-0.0008, 0.0006) 0.764 
Superior frontal gyrus -0.000004 (-0.0007, 0.0008) 0.993 -0.0002 (-0.001, 0.0007) 0.702 
Superior parietal gyrus 0.0003 (-0.0002, 0.0009) 0.251 0.0003 (-0.0004, 0.0009) 0.433 
Supramarginal gyrus 0.0001 (-0.0005, 0.0007) 0.712 -0.00009 (-0.0008, 0.0006) 0.811 
Temporal pole -0.0009 (-0.002, 0.0004) 0.162 -0.002 (-0.003, -0.0002) 0.027 
Average thickness  -0.0003 (-0.0009, 0.0003) 0.359 -0.0006 (-0.001, 0.00009) 0.090 
Average thickness is over the AD-specified areas. Model 1 (n=253) adjusted for age and sex. Model 2 
(n=235) adjusted for age, sex, race, education, depression, and medical conditions. 
 
 
Table 10. Cross-sectional association between baseline glucose (mg/dL) and cortical 
thickness at baseline by APOE status 
 APOE ε4 Positive (n=79) APOE ε4 Negative (n=168) 
 B (95% CI) p B (95% CI) p 
Superior parietal gyrus -0.001 (-0.002, 0.0005) 0.183 0.0007 (3.05e-6, 0.001) 0.049 
Temporal pole -0.004 (-0.008, -0.0009) 0.014 -0.0003 (-0.002, 0.001) 0.711 
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